April, 2014
CURRICULUM VITAE
Sewon Kang, M.D., M.P.H.
CURRENT POSITION
Noxell Professor of Dermatology
Chairman of the Department of Dermatology
Dermatologist-in-Chief, Johns Hopkins Hospital
Johns Hopkins Medicine
ADDRESS
Department of Dermatology
Cancer Research Building II, Suite 209
Johns Hopkins Medicine
1550 Orleans Street
Baltimore, Maryland 21231
Tel: (410) 955-8662
FAX: (410) 955-8645
Office:
EDUCATION
Graduate:
University of Michigan Medical School
Ann Arbor, Michigan
Degree: M.D., June 1987
University of Michigan School of Public Health
Ann Arbor, Michigan
Health Degree: M.P.H. in Epidemiology, August 1982
Undergraduate:
Williams College
Williamstown, Massachusetts
Degree: B.A. in Chemistry, June 1980
High School:
Glenbrook North High School
Northbrook, Illinois
September 1975 - June 1976
Sewon Kang, M.D.
Page 2
POSTGRADUATE TRAINING AND EDUCATION
Longwood Chief Resident (Brigham & Women’s, Beth Israel,
Boston Children’s, Dana Farber Hospitals) Department of
Dermatology, Harvard Medical School, Boston, Massachusetts
Residency, Department of Dermatology, Harvard Medical School
Massachusetts General Hospital, Boston, Massachusetts
Research Fellowship, Department of Dermatology, Harvard Medical School
Massachusetts General Hospital, Boston, Massachusetts
Internship, Department of Internal Medicine, University of Rochester
Strong Memorial Hospital, Rochester, New York
1991
1988 - 1992
1989 - 1990
1987 - 1988
ACADEMIC APPOINTMENT
Noxell Professor & Chair, Department of Dermatology
Johns Hopkins Medicine
Arthur C. Curtis Professor of Dermatologic Translational Research
University of Michigan Medical School
Professor (with tenure), Department of Dermatology
University of Michigan, Medical School
Associate Professor (with tenure), Department of Dermatology
University of Michigan Medical School
Assistant Professor, Department of Dermatology
University of Michigan Medical School
2008 - present
2008
2004 - 2008
1998 - 2004
1992 - 1998
HONORS AND AWARDS
Diversity Recognition Award, Diversity Leadership Council, Johns Hopkins
University
Presidential citation, American Academy of Dermatology
Instructional Development Fund Award, Center for Research on Learning
and Teaching, University of Michigan
Society for Investigative Dermatology, Galderma Acne Research Award
University of Michigan Medical School TAMS Award
University of Michigan Medical Student Award for Teaching Excellence
Finalist, Pre-Clinical Kaiser Permanente Award for Excellence in Teaching
University of Michigan Medical School Achievement in Clinical Research
Award
Alpha Omega Alpha Student Research Fellowship Mentor Stipend
University of Michigan Medical Student Teacher of the Month Award
University of Michigan Venture Investment Fund Award
Lotus Award from the University of Michigan United Asian-American
Medical Student Association
Outstanding Paper, Michigan Dermatologic Society
Outstanding Paper, Michigan Dermatologic Society
University of Michigan Faculty Travel Award
Dermatology Foundation Clinical Career Development Award in Vitamin
D3 and 9-cis Retinoic Acid interaction in normal and psoriatic skin
University of Michigan Minority Faculty Development Fund
Beiersdorf Travel Award in Dermatology
2011
2011
2006
2006
2005, 2007
1998, 2004
2003,‘04,’06,’07
2001
2001
2001
2000 - 2002
1999
1996
1995
1995
1994 - 1997
1993
1990
M.D. degree with distinction
University of Michigan Medical School Dean's Award for Research
University of Michigan President's Student Recognition Award
Academic All-American
American Dermatological Association Student Research Fellowship
National Psoriasis Foundation Summer Research Fellowship
HANA Scholar
Crusade Scholar
B.A. degree awarded with cum laude
Haystack Scholar, Williams College
Sewon Kang, M.D.
Page 3
1987
1987
1987
1987
1986
1984
1986 - 1987
1982 - 1986
1980
1977 - 1980
GRANTS
Current
National Institutes of Health & National Cancer Institute
(1R01CA161265-01)
“Hand-held infrared scanner for early detection of melanoma”
PI: Cila Herman, Ph.D
Co-Investigator: Sewon Kang, M.D.
2011-2016
Total cost: $ 560,000
Department of Defense, Classified
“Hyperspectral Imaging and Tagging System”
PI: Sewon Kang, MD
2010-2012
Total cost: $114,297
Department of Defense, Classified
“Site-Specific Morphology of Human Skin: Generation of Gene Expression Profile
Data to Develop Interventions to Transdifferentiate Stump Skin to Weight-Bearing
Acral Skin”
PI: Luis Garza, MD, PhD
Co-Investigator: Sewon Kang, MD
2010-2012
Total cost: $669,920
Selected Previous Grant Support
National Institutes of Health & National Center for Research Resources
(UL1RR024986 / KL2RR024987 / TL1RR024988)
“University of Michigan Clinical and Translational Science Award (UM CTSA)”
PI: Dan Clauw, MD
Program Director for Predoctoral Training Grant (TL1): Sewon Kang, MD
2007-2012
Total cost: $54,619,564
National Institutes of Health (1 T32 RR023257-01)
“University of Michigan multidisciplinary predoctoral clinical researchers in training
program (Roadmap T32)”
PI: Sewon Kang, MD
2005-2010
Total cost: $3,279,427
Sewon Kang, M.D.
Page 4
National Institutes of Health (R01 AG25186)
“Collagenase degradation of extracellular matrix in aging”
PI: Gary J Fisher, PhD
Co-Investigator: Sewon Kang, MD
2006-2011
Total cost: $1,710,000
Galderma
“A Comparative Study of Adapalene Gel, 0.3% versus Tretinoin 0.05% Emollient
Cream, for the Treatment of Photodamage”
PI: Sewon Kang, MD
2008-2010
Total cost: $179,688
Abbott
“A phase 3, multicenter study of the efficacy and safety of long-term Adalimumab
treatment in subjects with moderate to severe chronic plaque psoriasis”
PI: Sewon Kang, MD
2005-2008 Total cost: $279,816
Amgen
"Characterization of changes in skin-homing and potentially self-reactive circulating Tcells in psoriasis patients while taking etanercept"
PI: Sewon Kang, MD
2008-2010 Total Cost: $81,800.
National Institutes of Health (5R01 AR48077-05)
“UV-induced collagen reduction in treating skin of scleroderma”
PI: Sewon Kang, MD
2001-2007 Total cost: $1,887,500
National Institutes of Health (1R01 AG19364-01A1)
“TGF- Signaling in photoaged and chronically aged human skin”
PI: Gary J Fisher, PhD
Co-Investigator: Sewon Kang, MD
2002-2007 Total cost: $1,560,000
National Institutes of Health (1 K24 AR02159-01)
“Clinical translational research in dermatology and mentoring clinical investigators”
PI: Sewon Kang, MD
2000-2006 Total cost: $615,705
National Cancer Institute/Searle/Pharmacia
“A phase II/III randomized, double-blind, placebo-controlled clinical trial of Celecoxib in
subjects with actinic keratoses”
PI: Sewon Kang, MD
2001-2005 Total cost: $242,750
Johnson & Johnson
“Molecular mechanisms of skin repair”
PI: John J. Voorhees, MD
Co-Investigator & Director of Clinical Research: Sewon Kang, MD
Sewon Kang, M.D.
Page 5
1992-2005
Total cost: $33,000,000
National Institutes of Health (SBIR 1R43-AI30876)
“Topical delivery of liposomally-encapsulated interferon”
PI: Norman Weiner, Ph.D.
Co-Investigator: Sewon Kang, MD
1994-1996 Total cost: $362,944
Dermatology Foundation (Clinical Career Development Award)
“Vitamin D3 and 9-cis retinoic acid interaction in normal and psoriatic skin”
PI: Sewon Kang, MD
1994-1997 Total cost: $120,000
National Institutes of Health (1R01-AR4396201)
“Novel treatments for HIV-1 related Psoriasis”
PI: Brian J. Nickoloff, MD, PhD
Co-Investigator: Sewon Kang, MD
1995-1998 Total cost: $556,160
Amgen
“A multicenter, open-label, prospective study to evaluate the effectiveness and safety of
Etanercept in the treatment of subjects with psoriasis”
PI: Sewon Kang, MD
2004-2008 Total cost: $200,000
Immunex
“Double-blind, randomized, placebo-controlled phase II study of Enbrel (etanercept) in
the treatment of psoriasis”
PI: Sewon Kang, MD
2000-2001 Total cost: $56,056
IDEC
“A phase II open-label, multiple-dose, dose escalating study to evaluate the safety and
clinical activity of IDEC-131 in patients with moderate to severe plaque psoriasis”
PI: Sewon Kang, MD
2001-2001 Total cost: $91,600
University of Michigan Health System (Venture Investment Fund Award)
“UVA1 phototherapy for scleroderma”
PI: Sewon Kang, MD
2000-2002 Total cost: $252,396
Johnson & Johnson
“A two-year, double-blind, vehicle-controlled, randomized, multicenter study of Renova
0.05% in the treatment of photodamaged facial skin (Fitzpatrick skin types I, II, III)”
PI: Sewon Kang, MD
1999-2003 Total cost: $133,585
Pfizer
“A randomized, double-blind, double-dummy, placebo-controlled, multicenter study
Sewon Kang, M.D.
Page 6
assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of
moderate to severe age-related skin changes in postmenopausal women”
PI: Sewon Kang, MD
2000-2003 Total cost: $116,695
3M
“Vehicle-controlled, double-blind study to assess the safety and efficacy of Imiquimod
5% cream for the treatment of superficial basal cell carcinoma”
PI: Sewon Kang, MD
2001-2003 Total cost: $76,923
Novartis
“A 12-week, randomized, double-blind, placebo-controlled, multicenter, parallel-group,
dose-finding study to determine the dose-response, safety and tolerability of three doses
(10, 20, 30 mg bid) of SDZ ASM 981 tablets in subjects with chronic plaque-type
psoriasis”
PI: Sewon Kang, MD
2001-2002 Total cost: $45,549
Boehringer Ingelheim
“Phase II, randomized, double-blind, placebo controlled, multicenter, four week trial of
BIRB 796 BS 5, 10, 20 and 30 mg oral tablets versus placebo administered BID in
patients with moderate to severe plaque-type psoriasis”
PI: Sewon Kang, MD
2001-2003 Total cost: $184,169
Fujisawa
“Tacrolimus pharmacokinetics in adult atopic dermatitis patients after topical
administration of Protopic (Tacrolimus) ointment 0.03% and 0.1%”
PI: Sewon Kang, MD
2001-2003 Total cost: $115,800
Allergan
“A multi-center, double-blind, randomized, placebo-controlled study of the safety and
efficacy of 12 weeks treatment with Tazarotene 4.5 mg capsules once daily followed by a
12-week post-treatment follow-up period in patients with moderate to very severe plaque
psoriasis”
PI: Sewon Kang, MD
2002-2003 Total cost: $44,125
Allergan
“An evaluation of the safety and efficacy of Tazorac 0.1% cream (QD) and Renova
0.05% cream (QD) in the treatment of subjects with photodamaged facial skin”
PI: Sewon Kang, MD
2002-2003 Total cost: $105,644
Immunex
“Multicenter dose ranging study of the safety and efficacy of Enbrel in psoriasis”
PI: Sewon Kang, MD
2002-2003 Total cost: $125,200
Sewon Kang, M.D.
Page 7
CellGate
“A double-blind, placebo controlled, randomized, parallel group, dose and schedule
comparison of CGC2001 ointment in the treatment of patients with plaque psoriasis”
PI: Sewon Kang, MD
2002-2003 Total cost: $37,800
ICN Pharmaceuticals
“Nonablative laser therapy for acne vulgaris”
PI: Sewon Kang, MD
2002-2003 Total cost: $81,893
Centocor
“A phase 2, multicenter, randomized, double-blind, placebo-controlled trial evaluating
the efficacy and safety of Infliximab (Remicade) induction therapy in patients with
plaque-type psoriasis”
PI: Sewon Kang, MD
2002-2004 Total cost: $84,250
Connetics
“A phase III, multicenter, randomized, double-blind, active- and vehicle-controlled study
of the safety and efficacy of velac gel for the treatment of acne vulgaris”
PI: Sewon Kang, MD
2002-2004 Total cost: $131,250
Genmab
“A double-blind, placebo controlled, randomized, parallel group clinical trial of anti-CD4
receptor human monoclonal antibody (huMax-CD4) in patients with moderate to severe
chronic plaque psoriasis vulgaris”
PI: Sewon Kang, MD
2003-2004 Total cost: $35,813
Quatrx
“A multi-center, randomized, double-blind, vehicle-controlled, dose-finding, bilateral
plaque comparison study of the safety and efficacy of three concentrations of Qrx-101
ointment in the treatment of mild to moderate plaque psoriasis”
PI: Sewon Kang, MD
2003-2004 Total cost: $36,665
Abbott
“A phase II multicenter study of the safety and efficacy of adalimumab (D2E7) in
subjects with moderate to severe chronic plaque psoriasis”
PI: Sewon Kang, MD
2003-2004 Total cost: $125,490
Galderma
“A multicenter, randomized, double-blind, parallel group study to evaluate the safety and
efficacy of a fixed combination of Adapalene 0.1% and Benzoyl Peroxide 2.5%
(Adapalene and Benzoyl Peroxide topical gel) gel compared to its monads and topical gel
vehicle in subjects with acne vulgaris”
Sewon Kang, M.D.
Page 8
PI: Sewon Kang, MD
2004-2004 Total cost: $56,500
Centocor
“A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating
the efficacy and safety of infliximab induction therapy followed by multiple regimens of
maintenance infliximab therapy in subjects with plaque-type psoriasis”
PI: Sewon Kang, MD
2003-2005 Total cost: $191,000
3M
“Phase II, multiple-dose study to assess safety and efficacy of 0.03%, 0.1%, and 0.3%
concentrations of topical R-850 applied 1, 2, and 3 times a week for 4 weeks in subjects
with actinic keratosis”
PI: Sewon Kang, MD
2004-2005 Total cost: $68,546
SCIENTIFIC ACTIVITIES
Co-Director, Cutaneous Translational Research Program
Johns Hopkins School of Medicine
Director, Clinical Research Unit, Department of Dermatology
University of Michigan Medical Center, Ann Arbor, Michigan
Research Fellow, Department of Dermatology, Harvard Medical School
Massachusetts General Hospital, Boston, Massachusetts
Student Research Fellow, Department of Dermatology
University of Michigan Medical School, Ann Arbor, Michigan
Student Summer Research Fellow, The Salk Institute for Biologic Research
Tumor Virology Laboratory, La Jolla, California
2008 – present
1993 - 2008
1989 - 1990
1983 - 1987
1978 - 1980
TEACHING ACTIVITIES & APPOINTMENTS
Lectures
Lecturer; Genes to Society Cirriculum, Dermatology sequence,
Johns Hopkins School of Medicine
Lecturer; Pharmacology Core Curriculum, MS2, Johns Hopkins
University School of Medicine
Lecturer, Dermatology Core Curriculum, M2 Series, University of
Michigan Medical School
Lecture Series (1 hour weekly) for M4s on Dermatology Clinical Elective,
University of Michigan Medical School
2011 - present
2008 - present
1993-2008
1993-2008
Courses
Teaching Assistant, Depts. of Biology and Chemistry, Williams College
Teaching Assistant, Department of Chemistry, University of Michigan
1977-1980
1981
Creation of a Master’s Degree Curriculum
Master’s Degree in Clinical Research, University of Michigan
2006
Sewon Kang, M.D.
Page 9
Mentoring of Clinical/Translational Research Fellows
University of Michigan Undergraduates and Graduates
Jackie Neal
Angelica Susi
David Shen
Amy Kim
Darlene Kassab
Lauren Gold
Stacy Erndt
Londisa Halili
Noah Smith
Pamela Sharaf
Wendy Schumacher
Jennifer Rittenberry
George Kallingal
Claire Friedman
Jazmin Munoz
University of Michigan Medical Students
Beata Ryzik
Andy Suh
Padma Nallamothu
Reza Kafi
Le Yu
Raza Zaidi
Nada Elbuluk
Conroy Chow
Ladan Shahabi
Heh Shin Kwak
Semyon Zarkhin
Robert Egbers
Johns Hopkins Medical Students
Ian Rosenthal, Ph.D.
Nancy Cheng
Ashley Antony
Philip Song
Ashley Nieves (as Howard Hughes Medical Institute Fellow)
Alexander Fischer
Diane Kuhn
June Suh
Euphemia Mu
Minh-Huy Huynh
Other Medical School Students
Joyce Lee (U Penn)
Kathryn Boyse (Ohio State U)
Seung-Bok Lee (Seoul National University)
Jennifer Hung (King’s College, UK)
Hui Chen (University of Western Australia Melbourne Student)
Flora Poon (Bond University, Gold Coast, AUS)
Liliane Borik (Medical University of Vienna, AUT)
Dimitre da Silva (Federal University of Maranhao,BRA)
University of Michigan Dermatology Residents/Fellows
Neil Peters, MD
Mary Lu, MD
Renee Hamlet, MD
Kent Krach, MD
Greg Bezanis, MD
Valerie Hanft, MD
Michael Gifford, MD
Ana Petro, MD
Sandra Paek, MD
Yolanda Rosi, MD
Luis Garza, MD, PhD
Lisa Maier, MD
Frank Wang, MD
Nicole Neuschler, MD
Betsy Simon, MD
Anna Chien, MD
Mark Naftanel, MD
Kelly Cha, MD, PhD
Johns Hopkins Dermatology Residents/Fellows
Nada Elbuluk, MD
Cathy Lee, MD
Jo Martin, MD
Julie Zang, MD, PhD
Adrianna Jackson, MD
Yevgeniy Balagula, MD
Tamia Harris, MD, PhD
Crystal Agi, MD
Foreign Dermatology Fellows
Kwang Hyun Cho, MD, PhD
Byung Bok Lee, MD, PhD
Joo Heun Lee, MD, PhD
Tomas Dam, MD
Jong Yuk Lee, MD PhD
Hyun Chul Choi, MD
Sonyun Cho, MD, PhD
Jin Ho Chung, MD, PhD
Lone Anderson, MD, Ph.D
Jeffery Orringer, MD
Jennifer Burger, MD
Beata Ryzik, MD
Trisha Daley, MD
Abena Ofori, MD
Evans Bailey, MD, PhD
Missy Mesfin, MD
Mark Tran, MD
Molly Cavanaugh-Hussey, MD
Helena Pasieka, MD
Steve Yang, MD, PhD
Kwang Joong Kim, MD, PhD
Jeeho Choi, MD, PhD
Susan Bauer, MD
Moon Kyun Cho, PhD
Hye Jin Choi, MD
Woo Jin Yun, MD
Seong Guen Chi, MD
Barbara Summerer, MD
Thy Thy Do, MD
Boncheol Goo, MD
Kyung Hoon Park, MD
Sewon Kang, M.D.
Page 10
Wonju Lee, MD, PhD
Chong Won Choi, MD
Jeonghyun Shin, MD, PhD
Departmental Seminars
Update on Retinoids, yearly1 hour presentation
Update on Photoaging, yearly 1 hour presentation
Update on Immunopharmacology of Psoriasis, yearly 1 hour presentation
Training Grant Membership
Primary Preceptor, “Training Grant in Cell and Molecular Dermatology”,
National Institutes of Health Training Grant (T32-AR017979-26)
Primary Preceptor in Dermatology, “The University of Michigan Training
Program in Clinical Research”, National Institutes of Health Training
Grant (K30-HL004108-05)
1992-2008
1992-2008
1992-2008
1997-2008
1999-2008
Course Director
Director, Genes to Society Curriculum, Dermatology sequence, Johns Hopkins
School of Medicine
2011-present
Director, Dermatology Core Curriculum, M2 Series, University of
1995-2008
Michigan Medical School
Student Rotations (clinical)
Lecturer for Medical Students in Dermatology Clerkship, Harvard Medical
School
Examination Committee
In-Training Examination Contributor, American Board of Dermatology
1991
1997
Teaching Conferences
“The Best of UH Inpatient Consult Service”, monthly 1 hour presentation
to dermatology residents and clinical faculty
1993-2008
Attending Physician
University of Michigan Health System, Taubman Center, Department of
Dermatology
1992-2008
Clinical Clerkship Coordinator
Director, Dermatology Clinical Elective, University of Michigan Medical
School
1993-2008
Grand Rounds Presentation
Discussant/Presenter, monthy 2 hour program, Department of Dermatology 1992-2008
In-patient consulting
University of Michigan Health System
American Board of Dermatology
1993-2008
In-training examination contributor
Sewon Kang, M.D.
Page 11
1997
University of Michigan Medical School
Director, Dermatology Clinical Elective
Director, Dermatology Core Curriculum, M II Series
Lecturer, Dermatology Core Curriculum, M II Series
1993 - 2008
1995 - 2008
1993 - 2008
Harvard Medical School
Lecturer for Medical Students in Dermatology Clerkship
1991
University of Michigan Literature, Science & Art
Teaching Assistant, Organic Chemistry
1981
Williams College
Teaching Assistant, Departments of Biology and Chemistry
1977 - 1980
PROFESSIONAL EXPERIENCE
Biostatistician, Dermatopharmacology Unit
Department of Dermatology, University of Michigan Medical School
User-Friendly Computer Software Programmer
Office of Employee Health, University of Michigan Medical Center
MEMBERSHIPS IN PROFESSIONAL SOCIETY
American Acne & Rosacea Society
American Dermatological Association
Skin of Color Society
Korean Society for Psoriasis Research, Honorary Member
Korean-American University Professors Association
American Society for Clinical Pharmacology and Therapeutics
National Psoriasis Foundation
Dermatology Foundation
Inflammation Research Association
Skin Pharmacology Society
Michigan Dermatological Society
Korean Dermatologic Association of America
American Academy of Dermatology
Society for Investigative Dermatology
American Federation for Medical Research
Harvard House Officer’s Club
1982 - 1983
1984 - 1985
since 2005
since 2004
since 2002
since 1998
since 1996
since 1996
since 1996
since 1994
since 1993
since 1993
since 1993
since 1992
since 1992
since 1992
since 1989
since 1988
NATIONAL AND INTERNATIONAL COMMITTEES AND RESPONSIBILITIES
Society for Investigative Dermatology
Member, Executive Committee
2008 – 2010
Member, Committee on Finance
Board of Directors
International Task Force
Member, Committee on Education
Member, Committee on Albert M. Kligman Fellowships
Dermatology Foundation
Board of Trustees
Member, Annenberg Circle
Chair, Medical and Scientific Committee
Chair (Michigan), Leaders Society Campaign
Nominating Committee
Chair, Nominating Committee
Member, Medical and Scientific Committee
Vice Chair (Michigan), Leaders Society Campaign,
The Photomedicine Society
President
President-Elect
Board of Directors
American Acne & Rosacea Society
President - Elect
Founding Director
Chair, Scientific Committee
Board of Directors
Korean Dermatological Association
Member, Bidding Committee for the 2011 World Congress of
Dermatology
Skin of Color Society
A Founding Member of the Board of Directors
American Academy of Dermatology
Member, Development and Industry Liaison Committee
Member, Guidelines/Outcomes Task Force on Atopic Dermatitis
Member, Committee on Research
Working Group, Young Investigators in Dermatology Award
United States Pharmacopeia (USP) Drug Information
Expert Committee Member (Dermatology)
Korean Dermatologic Association of America
President
American Dermatological Association
Member, Audit committee
American Skin Association
Medical Advisory Board
Association of Professors of Dermatology
Board of Directors
Sewon Kang, M.D.
Page 12
2006 – 2009
2005 – 2010
2005 – 2007
2003 – 2008
1997 – 2000
2005 – present
2013 - present
2005
2004 – 2006
2004 – 2007
2006 – 2007
2003 – 2005
2000 – 2003
2012 - present
2006 – 2012
2003 – present
2013 - present
2005 – 2008
2005 – present
2009 – present
2005 - 2007
2002 - 2007
2007 - 2011
2001 – 2003
2008 – present
2011-2012
2000 – 2004
1999 – 2012
2009 – 2012
2011 – present
2012-2015
JOURNAL REVIEWER
Lupus
Translational Research
American Journal of Pathology
Journal of the European Academy of Dermatology
since 2013
since 2007
since 2006
since 2006
Journal of Immunology
The FASEB Journal
Journal of Cutaneous Medicine & Surgery
New England Journal of Medicine
Journal of Photochemical and Photobiological Sciences
Experimental Dermatology
Pediatric Dermatology
The Medical Letter on Drugs and Therapeutics
Photochemistry and Photobiology
Photodermatology, Photoimmunology & Photomedicine
Journal of Dermatological Treatment
Skin Pharmacology
Dermatology (Basel, Switzerland)
British Journal of Dermatology
Journal of Investigative Dermatology
Journal of the American Academy of Dermatology
Archives of Dermatology
Sewon Kang, M.D.
Page 13
since 2005
since 2004
since 2004
since 2002
since 2002
since 2002
since 2001
since 2001
since 2000
since 2000
since 1999
since 1998
since 1998
since 1998
since 1997
since 1992
since 1989
EDITORIAL RESPONSIBILITIES
Editor-in-Chief, Fitzpatrick’s Dermatology in General Medicine.
9th. Edition
Member, Editorial Board, Journal of the American Academy of
Dermatology
Member, Editorial Board, Clinical Dermatology (Seoul)
Member, Editorial Board, Photodermatology, Photoimmunology &
Photomedicine
2014 - present
1997 - 2008
1997 – present
2009 – present
GRANT REVIEWER
National Institutes of Health
a. National Institute of Arthritis and Musculoskeletal and Skin Diseases
1. Study Section, NIAMS Clinical Trials (2012-2016)
2. Special Emphasis Panel for MCRC applications
3. Biomarkers for Rheumatic and Skin Diseases
4. Special Emphasis Panel for K23 Career Development Award
5. Special Emphasis Panel for Dermatomyositis Clinical Trials
6. Chairperson for Special Emphasis Panel for K24 Midcareer
Investigator Award
7. Special Emphasis Panel for Loan Repayment Program
8. Hyperaccelerated Awards/mechanisms in Immunomodulation
Trials
9. R03, Special Emphasis Panel
10. R21, Pilot and Feasibility Clinical Research Grants
b. National Center for Complementary and Alternative medicine
Dermatology Foundation
Johns Hopkins Clinician Scientist Award
The University of Michigan Medical School Biomedical Research
Application- Basic Science Research Partnership
BC (British Columbia) Health Research Foundation
2001 – present
2003 – 2005
2012 - present
1997
1992
Sewon Kang, M.D.
Page 14
CERTIFICATION AND LICENSURE
Diplomate, American Board of Dermatology
(recertified thru:
Diplomate, National Board of Medical Examiners
1992
2023)
1988
ADMINISTRATIVE POSITIONS & UNIVERSITY COMMITTEES
Johns Hopkins Department of Dermatology
2008 – present
Noxell Professor and Chairman
Johns Hopkins Medicine
Chair, Department of Radiation/Oncology Review
Co-Chair, Task Force on Faculty Compensation
Ambulatory Joint Council
Ambulatory Oversight Committee
Committee on the Promotion of Academic Clinicians
Agenda Committee of the Advisory Board of the Medical Faculty
Search Committee, Chair of Otolaryngology
Advisory Board, Doris Duke Clinical Research Fellowship
Board of Governors, Clinical Practice Association
Review Committee, Clinician Scientist Career Development Award
Committee on Space
Standing Committee on Discipline
2014
2014
2013 - present
2013 - present
2009 – 2011
2009 – 2012
2010
2010 – 2013
2011 – 2014
2011 – present
2011 - present
2011 – 2012
University of Michigan Department of Dermatology
Member, Promotions Committee
Director, Clinical Research Unit
Clinical Research Director, University of Michigan/Johnson & Johnson
Research Alliance (1990 – 2002)
Member, Resident Selection Committee
Member, Five-Year Departmental Review Committee
Chief, Inpatient Consultation Service, University of Michigan Hospitals
2001 – 2008
1993 – 2008
1993 – 2002
1993 – 2008
1996
1994 - 2008
University of Michigan Medical School & Hospitals
CTSA Education Program Executive Committee
CTSA Clinical Trial Planning Grants Review Committee
Training and Education Workgroup, University of Michigan
NIH CTSA grant
Advisory Council Member, University of Michigan NIH
K12/K30 programs
Member, Medical Student Clinical Research Task Force
Ad Hoc Member, Committee on Sentinel/Adverse Event
Member, Committee on Medical Student Research
Faculty Career Advisor
2008 - 2008
2007
2005 - 2006
2005 - 2008
2005 - 2008
2002 - 2003
1984 - 1987; 1997 - 2008
1993 - 2008
Member, Diversity and Career Development Committee
Search Committee for Director of Dermatopathology
Member, Academic Review Board
Director, The XVII Midwest Student Medical Research Forum
Director, Medical Student Research Forum
Member, Student Council
Sewon Kang, M.D.
Page 15
1997 - 1999
1997 - 1998
1992 - 1993
1985 - 1986
1984 - 1987
1986 - 1987
Harvard Medical School Department of Dermatology
Member, Resident Selection Committee
Member, ABC Committee
1991 - 1992
1988 - 1992
ISSUED/FILED PATENTS
1999
Compositions for assessing 1,25(OH)2D3 activity in skin and for enhancing the
therapeutic use of 1,25(OH)2D3. US Patent # 5,998,393.
2000
Methods for inhibiting photoaging of skin. US Patent # 6,130,254.
2001
Methods and compositions for preventing and treating chronological aging in human
skin. U.S. Patent # 6,630,516.
2002
Use of natural EGFR inhibitors to prevent side-effects due to retinoid therapy, soaps,
and other stimuli that activate the epidermal growth factor-receptor. U.S. Patent #
6,638,543
2002
Methods for inhibiting photoaging of skin (a modification of US Patent # 6,130,254).
US Patent # 6,365,630.
2005
Methods and compositions for preventing and treating chronological aging in human
skin. (a modification of U.S. Patent # 6,630,516). US Patent # 6,919,072.
2006
Methods and compositions for treating rosacea. US Patent # 7,078,048.
2006
UVA (# 360-400) and UVB (300-325) specific sunscreens. US Patent # 7,147,863.
2007
Compositions and methods for use against acne-induced inflammation and dermal
matrix-degrading enzymes. US Patent 7,268,148
2010
Use of compositions for treating Rosacea. US Patent 7,795,302
2011 A minimally invasive skin biopsy devise for removal (cosmetic and diagnostic
purposes) of skin conditions in the epidermis. Filed.
2011 Method to use autologous fibroblasts to alter skin identity. Filed.
2012 Cryosyringe Designed for Sterile Liquid Nitrogen Freezing, Quick Thawing and
Injection of Cellular Slurries. Filed. JHU Reference #C12087
Sewon Kang, M.D.
Page 16
2013 Fiber optic sensor integrated clothing/harness for physiology assessment.
Files. JHU reference #C12584
BIBLIOGRAPHY
PUBLICATIONS IN SCIENTIFIC JOURNALS
1.
Vanderveen EE, Ellis CN, Kang S, Case P, Headington JT, Voorhees JJ, Swanson A:
Topical minoxidil for hair growth. J Am Acad Dermatol 1984;11:416-421
2.
Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN: Oral ibuprofen and
tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984;11:1076-1081
3.
Ellis CN, Kang S, Grekin RC, LoBuglio AF, Voorhees JJ: Etretinate therapy for
psoriasis reduces antibody-dependent cell-mediated cytotoxicity of polymorphonuclear
leukocytes. Arch Dermatol 1985;121:877-880
4.
Ellis CN, Kang S, Grekin RC, Voorhees JJ, Silva J: Etretinate therapy reduces PMNL
chemotaxis-enhancing properties of psoriatic serum. J Am Acad Dermatol 1985;13:437443
5.
Kang S, Ellis CN, Grekin RC, Hamilton TA, Voorhees JJ, LoBuglio AF: Etretinate
therapy and immune activities. Arch Dermatol 1986;122:629-630
6.
Ellis CN, Fallon JD, Kang S, Vanderveen EE, Voorhees JJ: Topical application of
nonsteroidal anti-inflammatory drugs prevents vehicle-induced improvement of psoriasis.
J Am Acad Dermatol 1986;14:39-43
7.
Wong RC, Gilbert M, Woo TY, Kang S, Peterson C, Ellis CN: Photosensitivity and
isotretinoin therapy. J Am Acad Dermatol 1986;14:1095-1096
8.
Ellis CN, Kang S, Vinik AI, Grekin RC, Cunningham WJ, Voorhees JJ: Glucose and
insulin responses are improved in psoriasis patients during therapy with etretinate, a
vitamin A derivative. Arch Dermatol 1987;123:471-475
9.
Berman R, Kang S, Imber M, Dover JS: Nevus spilus. J Am Acad Dermatol
1989;21:163-164
10.
Kang S, Dover JS: Successful therapy of pyoderma gangrenosum with intravenous
vancomycin and mezlocillin. Br J Dermatol 1990;123:389-393
11.
Kang S, Gonzalez E: Photoallergic contact dermatitis. J Am Acad Dermatol
1990;23:546-547
12.
Markowitz JA, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ, Cosimi AB:
Prognosis following initial recurrence of cutaneous melanoma. Arch Surg
1991;126:703-708
13.
Sewon Kang, M.D.
Page 17
Kang S, Barnhill RL, Graeme-Cook F, Randolph G, Nadol TB, Sober AJ: Primary
malignant melanoma of the external auditory canal: a case report with presentation as an
aural polyp. Am J Otol, 1992;13:194-196
14.
Kang S (consultant dermatologist): Case Records of the Massachusetts General Hospital.
A 56-year-old man with Waldenstrom's macroglobulinemia and cutaneous and oral
vesicles. Case of the Month. N Engl J Med, 1992;326:1276-1284
15.
Kang S, Barnhill RL, Mihm Jr MC, Sober AJ: Multiple primary cutaneous melanomas.
Cancer 1992;70:1911-1916
16.
Kenet RO, Kang S, Kenet BJ, Fitzpatrick TB, Sober AJ, Barnhill RL: Clinical diagnosis
of pigmented lesions using digital epiluminescence microscopy: grading protocol and
atlas. Arch Dermatol 1993;129:157-174
17.
Kang S, Barnhill RL, Mihm Jr MC, Sober AJ: Histologic regression in malignant
melanoma: an interobserver concordance study. J Cutan Pathol 1993;20:126-129
18.
Kang S, Fitzpatrick TB: Debilitating verruca vulgaris in a HIV infected patient:
dramatic improvement with hyperthermia therapy. Arch Dermatol 1994;130:294-296
19.
Kang S, Barnhill RL, Mihm Jr MC, Fitzpatrick TB, Sober AJ: Melanoma risk in
individuals with clinically atypical nevi. Arch Dermatol 1994;130:999-1001 (Selected
for reprinting in international edition and AMA Special Journal Abstracts, JAMA
1995;274:284C)
20.
Duraiswamy N, Tse Y, Hammerberg C, Kang S, Cooper KD: Distinction of class II
MHC+ langerhans cell-like interstitial dendritic antigen-presenting cells in murine dermis
from dermal macrophages. J Invest Dermatol 1994;103:678-683
21.
Barnhill RL, Aguiar M, Cohen C, Kang S, Kennedy J, Schmidt B, Sober AJ, Solomon
AR. Congenital melanocytic nevi and DNA content: an analysis by flow and image
cytometry. Cancer 1994;74:2935-2943
22.
Griffiths CEM, Tranfaglia MG, Kang S: Prolonged occlusion in the treatment of
psoriasis: A clinical and immunohistologic study. J Am Acad Dermatol 1995;32:618622
23.
Fisher GJ, Reddy AP, Datta SC, Kang S, Yi JY, Chambon P, Voorhees JJ: All-trans
retinoic acid induces cellular retinol-binding protein in human skin in-vivo. J Invest
Dermatol 1995;105:80-86
24.
Griffiths CEM, Kang S, Ellis CN, Kim KJ, Finkel LJ, Ortiz-Ferrer L, White GM,
Hamilton TA, Voorhees JJ: Two concentrations of topical tretinoin (retinoic acid) cause
similar improvement of photoaging but different degrees of irritation: a double-blind,
vehicle-controlled comparison of tretinoin 0.1% and 0.025% creams. Arch Dermatol
1995;131:1037-1044
25.
Sewon Kang, M.D.
Page 18
Kang S, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, Tavakkol A, Yi JY,
Griffiths CEM, Elder JT, Voorhees JJ: Application of retinol to human skin in-vivo
induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of
retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol
1995;105:549-556 ( Selected for In This Issue )
26.
Fader DJ, Kang S: Bedsore of unknown primary site. Arch Dermatol 1995;131:11151116
27.
Busam KJ, Berwick M, Blessing K, Fandrey K, Kang S, Karaoli T, Fine J, Cochran AJ,
White WL, Rivers J, Elder DE, Wen DRP, Heyman BH, Barnhill RL: Tumor vascularity
is not a prognostic factor for malignant melanoma of the skin. Am J Pathol
1995;147:1049-1056
28.
Fisher GJ, Datta S, Talwar HS, Wang ZQ, Varani J, Kang S, Voorhees JJ: Molecular
basis of sun-induced premature skin aging and retinoid antagonism. Nature
1996;379:335-339 (All authors contributed equally to this work)
29.
Stutz JA, Ellis CN, Kang S: Failure of topical polymyxin B to improve mild plaque
psoriasis. Arch Dermatol 1996;132:231
30.
Duell EA, Kang S, Voorhees JJ: Retinoic acid isomers applied to human skin in-vivo
each induce a 4-hydroxylase which inactivates only trans retinoic acid. J Invest
Dermatol 1996;106:316-320
31.
Kang S, Kim KJ, Griffiths CEM, Wong TY, Talwar HS, Fisher GJ, Gordon D, Hamilton
TA, Ellis CN, Voorhees JJ: Topical tretinoin (retinoic acid) improves early stretch
marks. Arch Dermatol 1996;132:519-526 ( selected for reprinting in international
edition and AMA Archives Journals Abstracts, JAMA 1997; 277:360e )
32.
Elder JT, Kaplan A, Cromie MA, Kang S, Voorhees JJ: Retinoid induction of CRABP-II
mRNA in human dermal fibroblasts: Use as a retinoid bioassay. J Invest Dermatol
1996;106:517-521
33.
Kang S, Li XY, Voorhees JJ: Pharmacology and molecular action of retinoids and
vitamin D in skin. J Invest Dermatol Symposium Proceedings 1996;1:15-21
34.
Kurlandsky SB, Duell EA, Kang S, Voorhees JJ, Fisher GJ: Auto-regulation of retinoic
acid biosynthesis through regulation of retinol esterification in human keratinocytes.
J Biol Chem 1996; 271:15346-15352
35.
Fader DJ, Kang S: Calciphylaxis without renal failure. Arch Dermatol 1996; 132:837838
36.
Kang S, Duell EA, Kim KJ, Voorhees JJ: Liarozole inhibits human epidermal retinoic
acid 4-hydroxylase activity and differentially augments human skin responses to retinoic
acid and retinol in-vivo. J Invest Dermatol 1996;107:183-187
37.
Sewon Kang, M.D.
Page 19
Duell EA, Derguini F, Kang S, Elder JT, Voorhees JJ: Extraction of human skin
epidermis treated with retinol yields retro retinoids in addition to free retinol and retinyl
esters. J Invest Dermatol 1996;107:178-182
38.
Loo DS, Kang S: Diffuse normolipemic plane xanthomas with monoclonal gammopathy
presenting as urticarial plaques. J Am Acad Dermatol 1996;35:829-832
39.
Chen GF, Kang K, Kang S, Rook AH, Kubin M, Voorhees JJ, Cooper KD:
Differential induction of IL-12 p40 and IL-10 mRNA in human Langerhans’ cells and
keratinocytes by in-vivo occlusion, vehicle and all-trans retinoic acid. J Cutan Med
Surg 1996;1:74-80
40.
Choi J-H, O'Conner TP, Kang S, Voorhees JJ, Fisher GJ: Activation of ribosomal
protein S6 kinase in psoriatic lesions and cultured human keratinocytes by epidermal
growth factor receptor ligands. J Invest Dermatol 1997;108:98-102
41.
Karimipour D, Johnson TM, Kang S, Wang TS, Lowe L: Mucinous carcinoma of the
skin. J Am Acad Dermatol, 1997;36:323-326
42.
Kang S, Li XY, Duell EA, Voorhees JJ: The retinoid-X-receptor agonist 9-cis-retinoic
acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25dihydroxyvitamin D3 in human skin in-vivo. J Invest Dermatol 1997;108:513-518
( Selected for In This Issue )
43.
Javier AF, Bata-Csorgo Zs, Ellis CN, Kang S, Voorhees JJ, Cooper KD: Rapamycin
(Sirolimus) inhibits proliferating cell nuclear antigen expression and arrests cell cycle in
the G1 phase in human keratinocyte stem cells. J Clin Invest 1997;99:2094-2099
44.
Kang S: Metabolism and molecular action of retinoid in human skin. Clin Dermatol
(Seoul) 1997;3:8-10
45.
Duell EA, Kang S, Voorhees JJ: Unoccluded retinol penetrates human skin in vivo more
effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol
1997;109:301-305
46.
Kang S, Fisher GJ, Voorhees JJ: Photoaging and topical tretinoin: therapy, pathogenesis,
and prevention. Arch Dermatol 1997;133:1280-1284
47.
Fisher GJ, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ: Pathophysiology of
premature skin aging induced by ultraviolet light. N Engl J Med 1997;337:1419-28
48.
Alaiti S, Kang S, Fiedler VC, Ellis CN, Spurlin DV, Fader D, Ulyanov G, Gadgil SD,
Tanase A, Lawrence I, Scotellaro P, Raye K, Bekersky I: Tacrolimus (FK-506) ointment
for atopic dermatitis: A phase I study in adults and children. J Am Acad Dermatol
1998;38:69-76
49.
Kang S, Yi S, Griffiths CEM, Fancher L, Hamilton TA, Choi JH: Calcipotriene-induced
improvement in psoriasis is associated with reduced interleukin-8 and increased
interleukin-10 levels within lesions. Br J Dermatol 1998;138:77-83
50.
Sewon Kang, M.D.
Page 20
Fisher GJ, Talwar H, Lin J, Lin P, McPhillips F, Wang ZQ, Li XY, Wan Y, Kang S,
Voorhees JJ: Retinoic acid inhibits induction of c-JUN protein by ultraviolet radiation
that occurs subsequent to activation of mitogen-activated protein kinase pathways in
human skin in-vivo. J Clin Invest 1998;101:1432-1440 (All authors contributed equally
to this work)
51.
Drake L, Babel D, Stewart DM, Rich P, Ling MR, Breneman D and 27 collaborating
investigators ( S Kang ): Once-weekly fluconazole (150, 300, or 450 mg) in the
treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol
1998;38:S87-94
52.
Ling MR, Swinyer LJ, Jarratt MT, Falo L, Monroe EW, Tharp M and 23 collaborating
investigators ( S Kang ): Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of
treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol
1998;38:S95-102
53.
Savin RC, Drake L, Babel D, Stewart DM, Rich P, Ling MR and 29 collaborating
investigators ( S Kang ): Pharmacokinetics of three once-weekly dosages of fluconazole
(150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad
Dermatol 1998;38:S110-116
54.
Musial J, Gluszko P, Undas A, Mahdi F, Kang S, Szczeklik A, Schmaier AH: Gamma
interferon administration to patients with atopic dermatitis inhibits fibrinolysis and
elevates C1 inhibitor. Thrombosis Research 1998;89:253-261
55.
Koo J, Abrams B, Albrecht G, Altmeyer P, Bahmer FA, Belaich S and 45 collaborating
investigators ( S Kang ): A randomized, double-blind study comparing the efficacy,
safety, and optimal dose of two formulations of cyclosporin in patients with severe
psoriasis. Br J Dermatol 1998;139:88-95
56.
Kang S, Voorhees JJ: Photoaging therapy with topical tretinoin: an evidence-based
analysis. J Am Acad Dermatol 1998;39:S55-61
57.
Kang S: Topical tretinoin therapy for management of early striae. J Am Acad Dermatol
1998;39:S90-92
58.
Varani J, Fisher GJ, Kang S, Voorhees JJ: Molecular mechanisms of intrinsic skin aging
and retinoid-induced repair and reversal. J Invest Dermatol Symposium Proceedings
1998;3:57-60
59.
Varani J, Kang S, Stoll S, Elder JT: Human psoriatic skin in organ culture: comparison
with normal skin exposed to exogenous growth factors and effects of an antibody to the
EGF receptor. Pathobiol 1998;66:253-259
60.
Wang ZQ, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ: Ultraviolet irradiation of
human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid
pre-treatment. Nature Medicine 1999;5:418-422
61.
Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A,
Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry K,
Sewon Kang, M.D.
Page 21
Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S: CTLA4Ig-mediated blockade of
T cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:12431252
62.
Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D and 18 collaborating
investigators ( S Kang): Finasteride in the treatment of men with frontal male pattern
hair loss. J Am Acad Dermatol 1999;40:930-937
63.
Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, Fisher GJ, Voorhees JJ:
1,25-dihydroxyvitamin D3 increases nuclear vitamin D receptors by blocking
ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrin
1999;13:1686-1694
64.
Dam TN, Kang S, Nickoloff BJ, Voorhees JJ: 1,25-Dihydroxycholecalciferol and
cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts
transplanted onto SCID mice. J Invest Dermatol 1999;113:1082-1089
65.
Varani J, Warner RL, Gharaee-Kermani M, Phan SH, Kang S, Chung JH, Wang ZQ,
Datta SC, Fisher GJ, Voorhees JJ: Vitamin A antagonizes decreased cell growth and
elevated collagen-degrading matrix metalloproteinases and stimulates collagen
accumulation in naturally aged human skin. J Invest Dermatol 2000;114:480-486
66.
Chung JH, Kang S, Varani J, Lin J, Fisher GJ, Voorhees JJ: Decreased extracellularsignal-regulated kinase and increased stress-activated MAP kinase activities in aged
human skin in vivo. J Invest Dermatol 2000;115:177-182
67.
Fisher GJ, Datta S, Wang ZQ, Li XY, Quan T, Chung JH, Kang S, Voorhees JJ: c-Jundependent inhibition of cutaneous procollagen transcription following ultraviolet
irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000;106:663-670
68.
Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, Lebwohl MG, Guzzo
CA, Jegasothy BV, Linsley PS, Krueger JG: Blockade of T lymphocyte costimulation
with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses
the cellular pathology of psoriatic plaques, including the activation of keratinocytes,
dendritic cells, and endothelial cells. J Exp Med 2000;192:681-693
69.
Gottlieb A, Krueger J, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M,
Wittkowski K, Ochs H, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M: Effects of
administration of a single dose of a humanized monoclonal antibody to CD11 on the
immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428-435
70.
Fleischer AB, Schwartzel EH, Colby SI, Altman DJ, and 32 collaborating investigators
( S Kang ): The combination of 2% 4-hydroxyanisole and 0.01% tretinoin is effective in
improving solar lentigines and related hyperpigmented lesions in two double-blind
multicenter clinical studies. J Am Acad Dermatol 2000;42:459-467
71.
Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM: Long-term safety and efficacy
of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad
Dermatol 2001;44:S58-S64
72.
Sewon Kang, M.D.
Page 22
Varani J, Spearman D, Perone P, Fligiel SEG, Datta SC, Wang ZQ, Shao Y, Kang S,
Fisher GJ, Voorhees JJ: Inhibition of type I procollagen synthesis by damaged collagen
in photoaged skin and by collagenase-degraded collagen in vitro. Am J Pathol
2001;158:931-942
73.
Watson REB, Craven NM, Kang S, Kielty CM, Griffiths CEM: A short-term screening
assay, using fibrillin-1 as a reporter molecule, for photoaging repair agents. J Invest
Dermatol 2001;116:672-678
74.
Fisher GJ, Choi HC, Bata-Csorgo Z, Shao Y, Datta S, Wang ZQ, Kang S, Voorhees JJ:
Ultraviolet irradiation increases matrix metalloproteinase-8 protein in human skin in vivo.
J Invest Dermatol 2001;117:219-226
75.
Bezanis GJ, Choi JH, Kang S: Immunomodulatory effects of vitamin D analogues in
psoriatic skin. Ann Dermatol 2001;13:201-204
76.
Kang S, Leyden JJ, Lowe NJ, Ortonne JP, Phillips TJ, Weinstein GD, Lew-Kaya DA,
Matsumoto RM, Sefton J, Walker PS, Gibson JR: Tazarotene cream for the treatment of
facial photodamage: A multicenter, investigator-masked, randomized, vehiclecontrolled, parallel comparison of tazarotene 0.01%, 0.025%, 0.05%, and 0.1% creams
and tretinoin 0.05% emollient cream applied once-daily for 24 weeks. Arch Dermatol
2001;137:1597-1604
77.
Thiboutot D, Gold M, Jarratt M, Kang S, Kaplan D, Millikan L, Wolfe J, Loesche C,
Baker M: Randomized, controlled trial of the tolerability, safety and efficacy of
adapalene gel 0.1% and tretinoin microsphere gel 0.1% in the treatment of acne vulgaris.
Cutis 2001;68:10-19
78.
Wolf JE, Taylor JR, Tschen E, Kang S: Topical 3.0% diclofenac in 2.5% hyaluronic
acid gel in the treatment of actinic keratoses. Intl J Dermatol 2001;40:709-713
79.
Varani J, Zeigler M, Dame MK, Kang S, Fisher GJ, Voorhees JJ, Stoll SW, Elder JT:
Heparin-binding epidermal-growth-factor-like growth factor activation of keratinocyte
ErbB receptors mediates epidermal hyperplasia, a prominent side-effect of retinoid
therapy. J Invest Dermatol 2001;117:1335-1341
80.
Lebwohl M, Elewski B, Eisen D, Savin RC and 11 collaborating investigators (S Kang):
Efficacy and safety of terbinafine (Lamisil®) 1% solution in the treatment of interdigital
tinea pedis and tinea corporis/cruris. Cutis 2001;67:261-266
81.
Quan T, He T, Kang S, Voorhees JJ, Fisher GJ: Connective tissue growth factor:
expression in human skin in vivo and inhibition by ultraviolet irradiation. J Invest
Dermatol 2002;118:402-8
82.
Quan T, He T, Kang S, Voorhees JJ, Fisher GJ: Ultraviolet Irradiation alters
Transforming Grown Factor /Smad Pathway in Human Skin in vivo. J Invest Dermatol
2002;119:499-506
83.
Sewon Kang, M.D.
Page 23
Chung JH, Seo JY, Lee MK, Lee JH, Kang S, Fisher GJ, and Voorhees JJ: Ultraviolet
modulation of human macrophage metalloelastase in human skin in vivo. J Invest
Dermatol 2002;119:507-512
84.
Fisher GJ, Kang S: Phototherapy for scleroderma: biological rationale, results and
promise. Curr Opin Rheumatol 2002;14:723-726
85.
Fisher GJ, Kang S, Varani J, Zsuzsanna BC, Wan Y, Datta S, Voorhees JJ: Mechanisms
of photoaging and chronological skin aging. Arch Dermatol 2002;138:1462-1470
86.
Kang S, Chung JH, Lee JH, Fisher GJ, Duell EA, Voorhees JJ: Topical N-acetyl
cysteine and genistein inhibit ultraviolet signaling that leads to photoaging in human skin
in vivo. J Invest Dermatol 2003;120: 835-841
87.
Fligiel SEG, Varani J, Datta SC, Kang S, Fisher GJ, Voorhees JJ: Collagen degradation
in aged/photodamaged skin in vivo and after exposure to matrix metalloproteinase-1 in
vitro. J Invest Dermatol 2003;120:842-848
88.
Kang S, Paller A, Soter N, Satoi Y, Rico MJ, Hanifin JM. Safe treatment of head/neck
AD with Tacrolimus ointment. J Dermatol Treat 2003;14:86-94
89.
Kang S, Goldfarb M, Weiss J, Metz R, Hamilton TA, Voorhees JJ, Griffiths CEM:
Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a
randomized trial. J Am Acad Dermatol 2003;49:83-90
90.
Brennan M, Bhatti H, Nerusu KC, Bhagavathula N, Kang S, Varani J, Voorhees JJ.
Matrix metalloproteinase-1 is the major collagenolytic enzyme responsible for collagen
damage in UV-irradiated human skin. Photochem Photobiol 2003;78:43-48
91.
Chung JH, Hanft VN, Kang S: Aging and photoaging. J Am Acad Dermatol
2003;49:690-697
92.
Petro A, Crofford L, Kang S: Infliximab: effective therapy for pustular psoriasis. Ann
Dermatol 2003;15:149-150
93.
Gottlieb A, Matheson R, Lowe N, Krueger G, Kang S, Goffe B, Gaspari A, Ling M,
Weinstein G, Nayak A, Gordon K, Zitnik R. A randomized trial of etanercept as
monotherapy for psoriasis. Arch Dermatol 2003;139:1627-1632
94.
Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik, BR, Margolis DJ, Schachner LA,
Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic
dermatitis. J Am Acad Dermatol 2004;50:391-404
95.
Leyden J, Bergfeld W, Drake L, Dunlap F, and 30 collaborating investigators (S Kang).
A systemic type I 5 α-reductase in the treatment of acne vulgaris. J Am Acad Dermatol
2004;50:443-447
96.
Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, AbdulGhani AA, Goldfarb M,
Chieffo N, Totoritis MC: Evaluation of safety and clinical activity of multiple doses of
Sewon Kang, M.D.
Page 24
the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe
plaque psoriasis. Clin Immuno 2004;111:28-37
97.
Orringer JS, Kang S, Hamilton T, Schumacher W, Cho S, Hammerberg C, Fisher GJ,
Karimipour DJ, Johnson TM, Voorhees JJ. Treatment of acne vulgaris with a pulsed dye
laser: a randomized controlled trial. JAMA 2004;291:2834-2839 (first two authors
contributed equally to this work)
98.
Orringer JS, Kang S, Johnson TM, Fisher GJ, Voorhees JJ. Pulsed dye laser treatment of
acne vulgaris. [letter] JAMA 2004;292:1430
99.
Lowe NJ, Gifford M, Tanghetti E, Poulin YP, Goldman M, Tse Y, Yamauchi P,
Rosenzweig H, Kang S. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream
in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized,
parallel-group study. J Cosmet Laser Ther 2004;6:79-85
100.
Varani J, Schuger L, Dame MK, Leonard C, Fligiel SEG, Kang S, Fisher GJ, Voorhees
JJ. Reduced fibroblast interaction with intact collagen as a mechanism for depressed
collagen synthesis in photodamaged skin. J Invest Dermatol 2004;122:1471-1479
101.
Quan T, He T, Kang S, Voorhees, J, Fisher G. Solar ultraviolet irradiation reduces
collagen in photoaged human skin by blocking transforming growth factor- type II
receptor/Smad signaling. Am J Pathol 2004;165:741-751
102.
Orringer J, Johnson T, Kang S, Karimipour D, Hammerberg C, Hamilton T, Voorhees JJ,
Fisher GJ. Effect of carbon dioxide laser resurfacing on epidermal p53 immunostaining
in photodamaged skin. Arch Dermatol 2004;140:1073-1077
103.
Kafi R, Fisher G, Quan T, Shao Y, Wang R, Voorhees JJ, Kang S. Ultraviolet A1
phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol
2004;140:1322-1324
104.
Orringer JS, Kang S, Johnson TM, Karimipour DJ, Hammerberg C, Voorhees JJ, Fisher
GJ. Connective tissue remodeling induced by CO2 laser resurfacing of photodamaged
human skin. Arch Dermatol 2004;140:1326-1332
105.
Rich P, Tschen EH, Jones T, Menter A, Lowe NJ, Eichenfield L, Hebert AA, Pariser D,
Savin RP, Smith SR, Jarratt M, Rodriguez D, Chalker DK, Kempers S, Ling M, Rafal
ES, Sullivan S, DiGiovanna JJ, Kang S, Shah LP, Wu E, Eberhardt DR, Chin C,
Ondovik M, Pak J, Bryce GF, and Khoo K-C: Effect of a single course of isotretinoin
therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular
acne. J Am Acad Dermatol 2004;51:709-717
106.
Kang S, Krueger G, Tanghetti E, Lew-Kaya D, Pharm D, Sefton J, Walker P, Gibson J:
A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment
of photodamage. J Am Acad Dermatol 2005;52:268-274
107.
Karimipour D, Kang S, Johnson T, Orringer J, Hamilton T, Hammerberg C, Voorhees JJ,
Fisher GJ. Microdermabrasion: a molecular analysis following a single treatment. J Am
Acad Dermatol 2005;52:215-223
Sewon Kang, M.D.
Page 25
108.
Rosi YL, Lowe L, Kang S. Treatment of hidradenitis supprativa with infliximab in a
patient with Crohn’s disease. J Dermatol Treatment 2005;16:58-62
109.
Varani J, Bhagavathula N, Scherzer H, Fay K, Boitano A, Glick G, Johnson K, Kang S,
Opipari A: A novel benzodiazepine selectively inhibits keratinocyte proliferation and
reduces retinoid-induced epidermal hyperplasia in organ-cultured human skin. J
Pharmacol Exp Ther 2005;313:56-63
110.
Kang S, Cho S, Chung JH, Fisher GJ, Voorhees JJ. Inflammation and extracellular
matrix degradation mediated by activated transcription factors NFkB and AP-1 in
inflammatory acne lesions in vivo. Am J Pathol 2005;166:1691-1699
111.
Kang S, Bergfeld W, Gottlieb A, Hickman J, Humeniuk J, Kempers S, Lebwohl M,
Lowe N, McMichael A, Milbauer J, Phillips T, Powers J, Rodriguez D, Savin R, Shavin
J, Sherer D, Silvis N, Weinstein R, Weiss J, Nighland M, Grossman R, Nyirady J. Long
term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of
photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin
Dermatol 2005; 6: 245-253.
112.
Cho S, Lowe L, Hamilton TA, Fisher GJ, Voorhees JJ, Kang S. Long term treatment of
photoaged human skin with topical retinoic acid improves epidermal cell atypia and
thickens collagen band in the papillary dermis. J Am Acad Dermatol 2005; 53:769-774.
113.
Orringer J, Voorhees JJ, Hamilton T, Hammerberg C, Kang S, Johnson T, Karimipour D,
Fisher G. Dermal matrix remodeling following non-ablative laser therapy. J Am Acad
Dermatol 2005; 53:775-782.
114.
Thiboutot D, Shalita A, Yamauchi P, Dawson C, Arsonnaud S, Kang S. Combination
therapy with adapalene gel 0.1% & doxcycline for severe acne vulagaris: A randomized
controlled study. SKINmed 2005; 4:138-146.
115.
Karimipour DJ, Kang S, Johnson TM, Orringer JS, Hamilton T, Hammerberg C,
Voorhees JJ, Fisher G. Microdermabrasion with and without aluminum oxide crystal
abrasion: A comparative molecular analysis of dermal remodeling. J Am Acad Dermatol
2006; 54:405-410.
116.
Thiboutot D, Shalita A, Yamauchi P, Dawson C, Kerrouche N, Arsonnaud S, Kang S.
Adapalene gel 0.1% as maintenance therapy for acne vulgaris: a randomized, controlled,
investigator-blind follow-up of a recent combination study. Arch Dermatol 2006;
142:597-602.
117.
Friedrich M, Bock D, Philipp S, Ludwig N, Sabat R, Wolk K, Schröter-Maas S, Aydt E,
Kang S, Dam T, Zahlten R, Sterry W, Wolff G. Pan-selectin antagonism improves
psoriasis manifestation in mice and man. Arch Dermatol Res 2006; 297:345-351.
118.
Rittié L, Varani J, Kang S, Voorhees JJ, Fisher G. Retinoid-induced epidermal
hyperplasia is mediated by epidermal growth factor receptor activation via specific
induction of its ligands heparin binding-EGF and amphiregulin in human skin in vivo. J
Invest Dermatol 2006; 126:732-739.
Sewon Kang, M.D.
Page 26
119.
Varani J, Dame M, Rittie L, Fligiel SEG, Kang S, Fisher G, Voorhees JJ. Decreased
collagen production in chronologically aged skin: Roles of age-dependent alteration in
fibroblast function and defective mechanical stimulation. Am J Pathol 2006; 168:18611868.
120.
Quan T, He T, Shao Y, Lin L, Kang S, Voorhees JJ, Fisher G. Elevated cysteine-rich 61
mediates aberrant collagen homeostasis in chronologically aged and photoaged skin. Am
J Pathol 2006; 169:482-490.
121.
Orringer J, Hammerberg C, Lowe L, Kang S, Johnson TM, Hamilton T, Voorhees JJ,
Fisher G. The effects of laser-mediated hair removal on the immunohistochemical
staining. J Am Acad Dermatol 2006; 55:402-407.
122.
Gordon KB, Langley RG Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller
B, Hamlin R, Lim L, Zhong J, Hoffman R, Chen DM. Clinical response to adlimumab
treatment in moderate to severe psoriasis patients: double-blinded, randomized clinical
trial and open-label extension study. J Am Acad Dermatol 2006; 55(4): 598-606.
123.
Wang F, Garza LA, Kang S, Varani J, Orringer JS, Hammerberg C, Fisher GJ, Voorhees
JJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic
acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007;
143:155-163.
124.
Orringer JS, Kang S, Maier L, Johnson TM, Sachs DL, Karimipour DJ, Helfrich YR,
Hamilton T, Voorhees JJ. A randomized, controlled, split-face clinical trial of 1320 nm
Nd:YAG laser therapy in the treatment of acne vulgaris. J Am Acad Dermatol 2007;
56:432-438.
125.
Helfrich YR, Yu L, Ofori A, Hamilton TA, Lambert J, King A, Voorhees JJ, Kang S.
Effect of smoking on aging of photoprotected skin: Evidence gathered using a new
photonumeric scale. Arch Dermatol 2007; 143:397-402. [Erratum Arch Dermatol 2007;
143:633]
126.
Schauber J, Dorschner RA, Coda AB, Büchua AS, Liu PT, Kiken D, Helfrich YR, Kang
S, Elalieh HZ, Steinmeyer A, Zügel U, Bikle DD, Modlin RL, Gallo RL. Injury enhances
TLR2 function and antimicrobial peptide expression through a Vitamin D-dependent
mechanism. J Clin Invest 2007; 117:803-811.
127.
Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A
randomized, open-label trial of continuous versus interrupted etanercept therapy in the
treatment of psoriasis. J Am Acad Dermatol 2007; 56:598-603.
128.
Helfrich YR, Kang S, Voorhees JJ. Topical becocalcidiol for the treatment of psoriasis
vulgaris: a randomized, placebo-controlled, double-blind, multi-center study. Br J
Dermatol 2007;157:369-374
129.
Cowen EW, Liu C, Steinberg SM, Kang S, Vonderheid EC, Kwak HSR, Booher S,
Petricoin EF, Liotta LA, Whiteley G, Hwang ST. Differentiation of tumor-phase mycosis
Sewon Kang, M.D.
Page 27
fungoides, psoriasis vulgaris, and normal controls in a pilot study using serum proteomic
analysis. Br J Dermatol 2007; 157: 946-953
130.
Kafi R, Kwak HSR, Schumacher W, Cho S, Hanft VN, Hamilton TA, King AL, Neal JD,
Varani J, Fisher G, Voorhees JJ, Kang S. Improvement of naturally aged skin with
vitamin A (retinol). Arch Dermatol 2007; 143:606-612.
131.
Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M,
Kang, S: Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of
acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am
Acad Dermatol 2007;57:791-9
132.
Bahagavthula N, Nerusu K, Hanosh A, Aslam M, Sundberg T, Opipari A, Johnson K,
Kang S, Glick G, Varani J. Bz-423, a novel benzodiazepine, suppresses keratinocyte
proliferation and has anti-psoriatic activity in the human skin-SCID mouse transplant
model. J Pharmaco 2008; 324:939-947
133.
Do TT, Zarkhin S, Orringer JS, Nemeth S, Hamilton TA, Sachs D, Voorhees JJ, Kang S.
Computer-assisted alignment and tracking of acne lesions indicate that most
inflammatory lesions arise from comedones and de novo. J Am Acad Dermatol 2008;
58: 603-608
134.
Varani J, Perone P, Warner R, Dame M, Kang S, Fisher G, Voorhees J. Vascular tube
formation on matrix metalloproteinase-1 damaged collagen. Br J Cancer 2008;98:164652
135.
Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, Hamilton TA, Mayes M,
Ratanatharathorn V, Voorhees JJ, Fisher GJ, Kang S. Increased pigmentation diminishes
anti-fibrotic response of human skin to ultraviolet A1 phototherapy. Arch Dermatol
2008; 144:851-858
136.
Orringer J, Hammerberg C, Hamilton T, Johnson T, Kang S, Sachs D, Fisher G,
Voorhees J. Molecular effects of photodynamic therapy for photoaging. Arch Dermatol
2008; 144:1296-1302
137.
Quan T, Qin Z, Xu Y, He T, Kang S, Voorhees J, Fisher G. Ultraviolet Irradiation
Induces CYR61/CCN1, A Novel Mediator of Collagen Hemeostasis, via Activation of
Transcription Factor AP-1 in Human Skin Fibroblasts. J Cell Communsignal 2008; 2(34):107-108
138.
Rittie L, Kang S, Voorhees J, Fisher G. Topical 17β estradiol stimulates collagen
production in sun-protected skin, but not in photoaged human skin in vivo. Arch
Dermatol 2008 144:1129-40
139.
Sachs DL, Kang S, Hammerberg C, Helfrich Y, Karimipour D, Orringer J, Johnson T,
Hamilton T, Fisher G, Voorhees J. The effects of Topical 5-fluorouracil improves actinic
keratoses and photoaged skin: clinical and molecular analysis. Arch Dermatol 2009;
145:659-666
140.
Sewon Kang, M.D.
Page 28
Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden J, Shalita A, Lozada V.
New insights into the management of acne: an update from the global alliance to improve
outcomes in acne group. J Am Acad Dermatol 2009; 60:S1-50
141.
Do T, Bailey E, Wang F, Smith N, Lee W, Fisher G, Voorhees J, Kang S. Targeted
broadband UVB phototherapy improves disorders characterized by increased dermal
matrix. Br J Dermatol 2009;161:1405-1407
142.
Fisher G, Quan T, He T, Shao Y, Cho M, Varani J, Kang S. Voorhees J. Collagen
fragmentation promotes oxidative stress and elevates matrix metalloproteinase -1 in
fibroblasts in aged human skin. Am J Pathol 2009;174:101-14
143.
Rittie L, Stoll S, Kang S, Voorhees J, Fisher G. Hedgehog signaling maintains hair
follicle stem cell phenotype in young and aged human skin. Aging Cell 2009; 8:738-751
144.
Wang F, Kwak HR, Elbuluk N, King AL, Hamilton TH Duell EA, Voorhees J, Fisher G,
Kang S. Correlation of CYP26 inducibility with clinical response to isotretinoin. J Am
Acad Dermatol 2009;61:252-258
145.
Elmets C, Viner J, Pentland A, Cantrell W, Bailey H, Kang S, Linden K, Hefferman M,
Duvie M, Elewski B, Umar A, Lin H, Bell W, Gordon G. Chemoprevention of NonMelanoma Skin Cancer with Celecoxib. J Natl Cancer Inst 2010; 10:1835-44;
146.
Leyden JJ, Gollnick H, Thiboutot D, Dreno B, Bettoli V, Kang S, Shalita A, Torres V.
The hypothetical role of Fox01 in acne is interesting, but more study is needed before any
conclusions can be drawn. Br J Dermatol, 2010; 163(6): 1365-6
147.
Johnson A, Xing X, Guzman A, Riblett M, Loyd C, Ward N, Wohn C, Prens E, Wang F,
Maier L, Kang S, Voorhees J, Elder J and Gudjonsson J. IL-1F5, F6, F8, and F9: a
novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte
antimicrobial peptide expression. J Immunol 2011; 186: 2613-22
148.
Nesterovitch A, Gyorfy A, Hoffman, M, Moore E, Elbuluk N, Tryniszewska B, Rauch T,
Simon M, Kang S, Fisher G, Mikecz K, Tharp M, and Glant T. Diministhed Function of
Protein Tyrosine Phosphatase Non-receptor Type-6 (PTPN6/SHP-1) May Contribute to
Clinical Symptoms of Neutrophilic Dermatoses (Pyoderma Gangrenosum and Sweet’s
Syndrome) Am J Pathol 2011; 178 (4): 1434-1441
149.
Grekin S, Mesfin M, Kang S, Fullen D. Intravascular histiocytosis following placement
of a metal implant. J Cutan Pathol 2011; 38:351-3
150.
Abad-Casintahan F, Chow S, Goh C, Kubba R, Miyachi Y, Noppakun N, See J, Suh D,
Yang L, Kang S. Toward evidence-based practice in acne: Consensus of an Asian
Working Group. J Dermatol 2011; 38(11): 1041-1048
151.
Lange J, Kang S, Balch C. Melanoma in the older patient: measuring frailty as an index
of survival. Ann Surg Oncol 2011;18: 3531-3532
152.
Loyo M, Schussel J, Colantuoni E, Califano J, Brait M, Kang S, Koch WM, Sidransky D,
Westra WH, Taube JM. Detection of Merkel cell virus and correlation with histologic
Sewon Kang, M.D.
Page 29
presence of Merkel cell carcinoma in sentinel lymph nodes. Br J Cancer 2012;106:1314–
1319
153.
Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, Chen C Riblett M,
Johnston A, Gudjonsson JE, Helfrich Y, Kang S, Fisher GJ, Voorhees JJ. Etanercept
suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal
expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol, 2012; 167:92-102
154.
Thiboutot D, Gollnick H, Bettoli V, Dreno B, Kang S, Leyden JJ, Shalita A, Torres V,
Global Alliance to Improve outcomes in Acne. Oral isotretinoin and pregnancy
prevention programmes. Br J Dermatol, 2012; 166(2): 466-7
155.
Shin, J. Vincent JG, Cuda JD, Xu H, Kang S. Kim J. Taube JM. Sox10 is expressed in
primary melanocytic neoplasms of various histologies but not in fibrohistrocytic
proliferations and histocytoses. J Am Acad Dermatol 2012;67(4): 717-26
156.
Yang NB, Garza LA, Foote CE, Kang S, Meyerle JH. High prevalence of stump
dermatoses remain prevalent in Vietnam veterans 40 years after amputation. Arch
Dermatol 2012; 148(11): 1283-1286
157.
Finley AY, Torres V, Kang S, Bettoli V, Dreno B, Goh CL, Gollnick H. Classification
of acne scars is difficult even for acne experts. J Eur Acad Dermatol Venereol 2013; 27:
391-393
158.
Johnston A, Guzman AM, Swindell WR, Wang F, Kang S, Gudjonsson JE. Early tissue
responses in psoriasis to the ant-TNF-α biologic etanercept suggest reduced IL-17R
expression and signaling. Br J Dermatol 2014; 1-2
159.
Wang F, Smith N, Tran B, Kang S, Voorhees J, Fisher G. Dermal damage promoted by
repeated low – level UV-A1 exposure despite tanning response in human skin. JAMA
Dermatol 2014;150(4):401-406
Accepted for Publication
160.
Balagula, Y, Kang, S, Patel, M. Synergism between mTOR pathway and ultraviolet
radiation in the pathogenesis of squamous cell carcinoma and its implication for solidorgan transplant recipients (2013)
Submitted for Publication
161.
Kang S, Voorhees JJ. Future perspectives for clinical investigation with RAMBAs.
162.
Phillips T, Goldman M, Kang S, Lee P, Stromberg K, Mann M, Lee J. A cosmetic
outcome scale to assess irregular skin pigmentation and wrinkling severity.
163.
Garza LA, Wang F, Fisher GJ, Cho S, Kafi R, Mayes M, Ratanatharathorn V, Voorhees
JJ, Kang S. Ultraviolet A1 therapy for fibrotic skin conditions.
164.
Gollnick H, Thiboutot D, Bettoli V, Dreno B, Kang S, Leyden J, Shalita A, Torres V.
Oral isotretinoin and pregnancy prevention programs.
Sewon Kang, M.D.
Page 30
165.
Vyas S, Banerjee A, Kang S, Garza L, Burlina P. Modeling skin constituents from in
vivo human skin hyperspectral signatures using machine learning regression.
166.
Cavanaugh-Hussey, MW, Mu E, Wang, T, Balch, C, Kang, S. Inverse Relationship
between Melanoma Death and Sentinel Lymph Node Metastases by Age in the SEER
Databases (2003-2009)
167.
Poon F, Kang S, Chien A. Mechanisms and treatment of photoaging.
168.
Kang S. Improving AKN with targeted ultraviolet B treatment: prospective , randomized,
split-scalp composition study.
169.
Kang S. Synergistic age and sun-exposure-related widespread genomic blocks of
hypomethylatin in nonmalignant skin.
170.
Dréno B, Thiboutot D, Layton A, Berson D, Perez M, Kang S. Large-scale international
study enhances understanding of an emerging acne population: adult females.
Non-Peer Reviewed Publications
171.
Kang S, Sober AJ: Childhood melanoma. The Melanoma Letter, 1991;9:1
172.
Kang S: Computers in the evaluation of pigmented lesions. The Skin Cancer
Foundation Journal, 1992;10:35
173.
Kang S: Calcipotriene: A modern psoriasis medicine with ties to rickets. J Geriatr
Dermatol 1995; 3SB:28B-32B
174.
Kang S: Photoaging and tretinoin. Dermatologic Clinics, 1998;16:357-364
175.
Johnson TM, Sondak VK, Su LD, Headington JT, Kang S, Lowe L: Is it a benign spitz
nevus or a malignant melanoma? Primary Care & Cancer, 2000;20:41-44
CHAPTERS IN BOOKS & EDITED SPECIAL JOURNAL ISSUES
1.
Kang S, Serri F, Sober AJ: Regressing Melanoma and Depigmentation, in Cascienelli N,
Santinami M, Veronesi U (editors) Cutaneous Melanoma Biology and Management.
Milano, Masson, 1990;159-166
2.
Kang S, Milton GW, Sober AJ: Childhood Melanoma, in Balch CM, Sober AJ (editors)
Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide (2nd.
edition). Philadelphia, JB Lippincott Co., 1992;312-318
3.
Kang S, Sober AJ: Pigmentary Disorders, in Rakel R (editor) Conn's Current Therapy,
1992 Edition. Philadelphia, WB Saunders, 1992;793-796
4.
Sober AJ, Kang S, Barnhill RL: Discerning Individuals at Elevated Risk for Cutaneous
Melanoma, in Rampen FHJ (editor) Clinics in Dermatology, 1992;9:15-20
Sewon Kang, M.D.
Page 31
5.
Kang S: Seborrheic Dermatitis, in Arndt KA, et al. (editors) Manual of Clinical
Problems in Dermatology. Boston, Little, Brown and Company, 1992;77-81
6.
Kang S: Pyoderma, in Arndt KA, et al. (editors) Manual of Clinical Problems in
Dermatology. Boston, Little, Brown and Company, 1992;137-142
7.
Kang S: Pyoderma Gangrenosum, in Arndt KA, et al. (editors) Manual of Clinical
Problems in Dermatology. Boston, Little, Brown and Company, 1992;300-303
8.
Kang S, Sober AJ: Disturbances in Melanin Pigmentation, in Moschella SL, Hurley H
(editors) Dermatology (3rd. edition). Philadelphia, WB Saunders, 1992;2:1442-1474
9.
Kang S, Lerner EA, Sober AJ, Levine N: Pigmentary Disorders from Exogenous
Causes, in Levine N, Maibach HI (editors) Pigmentation and Pigmentary Disorders.
Boca Raton, CRC Press, Inc., 1993;417-438
10.
Kang S, Griffiths CEM, Voorhees JJ: Photoaging: Mechanisms of retinoic acid-induced
improvement, in Bernard BA, Shroot B (editors) From Molecular Biology to
Therapeutics, Pharmacology and the Skin. Basel, Karger Series, 1993;5:40-45
11.
Kang S, Voorhees JJ: Topical retinoids, in Freedberg IM, Eisen AZ, Wolff K, Austen
KF, Goldsmith LA, Katz SI, Fitzpatrick TB (editors) Fitzpatrick's Dermatology in
General Medicine (fifth edition) McGraw-Hill, 1998;2726-2733
12.
Kang S, Voorhees JJ: Immunopathogenesis of psoriasis, in van de Kerkhof P (editor)
Textbook of Psoriasis. Oxford, Blackwell Science, 1999;106-118.
13.
Kang S, Voorhees JJ: Retinoids in psoriasis, in Christophers E, Wolff K (editors)
Dermatologic Therapy (a special issue on The Treatment of Psoriasis). Copenhagen,
Munksgaard, 1999;11:67-74
14.
Chung JH, Kang S, Fisher GJ: The molecular mechanisms of retinoid effects in human
skin, Clinics in Dermatology. Advances in Dermatology, 1999;15:367-393
15.
Kang S, Fisher GJ, Voorhees JJ: Pharmacology and molecular mechanisms of retinoid
action in skin, in Livrea MA (editor) Vitamin A and Retinoids: An Update of Biological
Aspects and Clinical Applications (Molecular and Cell Biology Update). Basel,
Birkhauser, 2000;151-159
16.
Kang S: Interaction of vitamin D and retinoids, in Kragballe K (editor) Vitamin D in
Dermatology. New York, Marcel Dekker, 2000;157-167
17.
Sachs D, Baur S, Kang S: Topical vitamin D, in Wolverton SE (editor) Comprehensive
Dermatologic Drug Therapy. Philadelphia, WB Saunders Co, 2001;685-694
18.
Kang S, Fisher GJ, Voorhees JJ: Photoaging: pathogenesis, prevention and treatment, in
Gilchrest BA (editor) Geriatric Dermatology, Clinics in Geriatric Medicine.
Philadelphia, WB Saunders Co, 2001,17:643-659
19.
Sewon Kang, M.D.
Page 32
Kang S, Voorhees JJ: Topical retinoids, in Freedberg IM, Eisen AZ, Wolff K, Austen
KF, Goldsmith LA, Katz SI, Fitzpatrick TB (editors) Fitzpatrick's Dermatology in
General Medicine (sixth edition) McGraw-Hill, 2003;2328-2334
20.
Kang S, Cho S, Voorhees JJ: Immunopathogenesis of psoriasis, in van de Kerkhof P
(editor) Textbook of Psoriasis (second edition). Oxford, 2003; 110-123
21.
Chung JH, Cho S, Kang S: Why does the skin age? Intrinsic aging, photoaging, and
their pathophysiology, in Rigel D, Weiss B, Lim H, Dover J (editors) Photoaging.
Marcel Dekker, 2004; 1-13
22.
Kang S (Guest Editor): An update on the use of retinoids in dermatology. Dermatologic
Therapy. Munksgaard Ltd, 2006; 19(5): September/October
23.
Rosi Y, Sachs D, Kang S: Topical vitamin D, in Wolverton SE (editor) Comprehensive
Dermatologic Drug Therapy (2nd Edition). Philadelphia, WB Saunders Co, 2007; 691699
24.
Kang S, Voorhees JJ: Topical retinoids, in Wolff K, Goldsmith LA, Katz SI, Gilchrest
B, Paller AS, Leffell DJ (editors) Fitzpatrick's Dermatology in General Medicine
(seventh edition), McGraw-Hill, 2008; 2106-2112
25.
Do T, Patel M, Kang S: Scarring, in Shalita A, DelRosso J, Webster G (editors) Acne
Vulgaris, Informa Healthcare, 2011; 43-56
26.
Fox M, Helfrich Y, Kang S: Other topical medications, in Bolognia JL, Jorizzo JL,
Shaffer JV (editors) Dermatology (third edition), Elsevier 2012; 2153-2164.
27.
Chien A, Voorhees JJ, Kang S: Topical retinoids in Wolff K, Goldsmith LA, Katz SI,
Gilchrest B, Paller AS, Leffell DJ (editors) Fitzpatrick's Dermatology in General
Medicine (Eighth edition), McGraw-Hill, 2013; 2665-2672.
28.
Summerer B, Kang S, Wang T: Preventing melanoma in Sharfman W (editor) Emerging
Cancer Thesspentics, Demo Medical Publishing, 2013; 391-404.
29.
Chien A, Mu E, Kang S: Skin in Osteogenesis Imperfecta in Sharpiro (editor)
Osteogenesis Imperfecta (in press).
30.
Cho S, Kang S: What’s new in acne pathogenesis in Kubba R (editor) World Clinics in
Dermatology Jay/zee Brothers Medical Publishers, 2013; 1 - 30.
31.
Han A, Chien A, Kang S. Photoaging. Dermatology Clinics: Photodermatology
PRESENTATIONS: INTERNATIONAL
1.
Computerized digital photography in the pigmented lesions clinic. Clinical Dermatology
in the Year 2000, London, May 1990
2.
Sewon Kang, M.D.
Page 33
Melanoma and melanoma precursors - pigment pattern characterization in vivo using
computer-assisted epiluminescence microscopy. XIV International Pigment Cell
Conference, Kobe, Japan, October 1990
3.
Identification of populations-at-risk for melanoma and epithelial skin cancer using skin
phototyping. European Society for Pigment Cell Research, Amsterdam, September 1991
4.
Natural history and prognosis of cutaneous melanoma. The 7th Korea-Japan Joint
Meeting of Dermatology, Seoul, Korea, October 1991
5.
Childhood melanoma and Spitz nevi. Advances in the Biology and Clinical Management
of Melanoma, Houston, November 1991
6.
Paraneoplastic pemphigus in Waldenstrom's macroglobulinemia. 18th World Congress
of Dermatology, New York, June 1992
7.
Identification of populations-at-risk for melanoma and epithelial skin cancer using skin
phototyping. 18th World Congress of Dermatology, New York, June 1992
8.
Digital imaging and epiluminescence microscopy. 18th World Congress of Dermatology,
New York, June 1992
9.
Melanoma screening with digital epiluminescence microscopy. Third International
Conference on Melanoma, Venice, Italy, March 1993
10.
Skin phototype and melanoma. Third International Conference on Melanoma, Venice,
Italy, March 1993
11.
Retinol elicits epidermal acanthosis and CRABP-II mRNA expression, but insignificant
erythema when topically applied to human skin. The Second Tricontinental Meeting of
the JSID, SID and ESDR, Kyoto, Japan, October 1993
12.
Vitamins and hormones in the skin. Department of Dermatology, Asian Medical Center,
Ulsan University College of Medicine, Seoul, Korea, October 1993
13.
Cutaneous effects of topical retinol in human skin. Department of Dermatology, Seoul
National University College of Medicine, Seoul, Korea, October 1993
14.
Retinol applied to human skin in-vivo produces histologic and molecular changes
characteristic of retinoic acid exposure but without measurable retinoic acid increase or
irritation. American Association for Cancer Research, Special Conference on
Mechanism of Action of Retinoids, Vitamin D and Steroid Hormones, Whistler, Canada,
January 1995
15.
Retinoid metabolism in human skin in-vivo. Department of Dermatology, Catholic
University Medical Center, Seoul, Korea, May 1995
16.
Metabolism of vitamin D and its molecular mechanism of action in human skin.
Department of Dermatology, Ulsan University College of Medicine, Seoul, Korea, May
1995
Sewon Kang, M.D.
Page 34
17.
Cytochrome P-450-mediated inactivation of retinoic acid in human skin. Department of
Dermatology, Kosin Medical College, Pusan, Korea, May 1995
18.
Topical tretinoin (retinoic acid) improves early stretch marks. European Retinoid
Research Group. Sophia Antipolis, France, October, 1995
19.
Pharmacokinetic findings from a topical FK-506 study in children with atopic dermatitis.
The Clinical Dermatology 2000, An International Congress, Vancouver, Canada, May
1996
20.
Retinoic acid therapy of skin diseases. The Clinical Dermatology 2000, An International
Congress, Vancouver, Canada, May 1996
21.
Calcipotriene treatment of psoriasis results in an early induction of interleukin-10 and a
concomitant reduction in interleukin-8 levels. Psoriasis: From Gene to Clinic, London,
UK, December 1996
22.
Metabolism and molecular action of retinoids in human skin in-vivo. Department of
Dermatology, Seoul National University, College of Medicine, Seoul, Korea, January,
1997
23.
Calcipotriene-induced improvement in psoriasis is causally associated with early
modulations of interleukins 10 and 8. 19th World Congress of Dermatology, Sydney,
Australia, June, 1997
24.
Targeting cytochrome P-450 as an approach to safely deliver retinoid action to human
skin. Dermatology Update, Montreal, Canada, October, 1997
25.
Enhancing retinoid and vitamin D3 effects by inhibiting the 4- and 24-hydroxylases.
Symposium on New Strategies in the Treatment of Skin Diseases- Focus on Cytochrome
P450, Cologne, Germany, May, 1998
26.
Glucocorticoid and retinoic acid inhibit UV irradiation induction of cytokine and matrixdegrading metalloproteinase genes through distinct mechanisms in human skin in vivo.
International Investigative Dermatology, Cologne, Germany, May, 1998
27.
Pharmacologic evidence for psoriasis as an immunological disease (Invited Plenary
Lecture). Korean Society for Psoriasis Research, Seoul, Korea, May, 1998
28.
Skin aging- current concept and treatment (Invited Plenary Lecture). The 50th Annual
Meeting of the Korean Dermatological Association, Seoul, Korea, October, 1998
29.
Photoaging- effective management based on patho-physiology. Third Annual
International Symposium on Aging Skin, San Francisco, California, January, 1999
30.
Immunomodulatory effects of vitamin D analogues in psoriatic skin. Fourth International
Calcipotriol Symposium - Vitamin D in Dermatology, Barcelona, Spain, April, 1999
31.
Sewon Kang, M.D.
Page 35
Evidence based management of aged and photoaged skin. Dermatology Update for the
Millennium, San Francisco, California, October, 1999
32.
Cutaneous retinoid metabolism and its effect on vitamin D signaling. Athens
Dermatology Symposium: Modern Trends in Skin Pharmacology- Molecular and
Clinical Aspects, Athens, Greece, June 2000
33.
Evidence-based therapy with retinoids in dermatology. Department of Dermatology,
University of Tokyo, Japan, August, 2000
34.
Distinguishing the cutaneous effect and side-effect of topical retinoids. Department of
Dermatology, Kobe University, Kobe, Japan, August 2000
35.
Evidence-based therapy with retinoids in dermatology. Keio University, Tokyo, Japan,
August 2000
36.
Retinoid signaling in human skin in vivo (Invited Plenary Lecture). 25th Annual Meeting
of the Japanese Society for Investigative Dermatology, Gifu, Japan, September, 2000
37.
Adapalene gel for the treatment of actinic keratoses. Differin Five-Year Anniversary
Symposium, Cannes, France, October, 2000
38.
Molecular dissection of retinoid dermatitis. Department of Dermatology, Seoul National
University, College of Medicine, Seoul, Korea, October, 2000
39.
Retinoid signaling in human skin- adapalene’s mode of action. The 52nd Annual Meeting
of the Korean Dermatological Association, Seoul, Korea, October, 2000
40.
Molecular basis for retinoid irritation. Department of Dermatology, Yonsei University,
College of Medicine, Seoul, Korea, October, 2000
41.
Retinoids for aging skin. The 5th International Symposium on Aging Skin, Coronado,
California, May, 2001
42.
Cytotoxic T lymphocyte associated antigen (CTLA)-4Ig. 2nd Joint Meeting of
International Psoriasis Symposium and the European Congress on Psoriasis, San
Francisco, June, 2001
43.
A new concept in acne pathophysiology – implications in treatment. The 12th JapanKorea Joint Meeting of Dermatology, Tokyo, Japan, November, 2001
44.
Randomized efficacy and safety assessment of adapalene gel (0.1% and 0.3%) and
vehicle for the treatment of actinic keratoses and lentigines. 20th World Congress of
Dermatology, Paris, France, July 1, 2002
45.
Current perspectives on acne inflammation and scarring. 20th World Congress of
Dermatology, Paris, France, July 3, 2002
46.
Sewon Kang, M.D.
Page 36
Nephrogenic fibrosing dermopathy: a new entity that responds to UVA1. Department of
Dermatology, Seoul National University, College of Medicine, Seoul, Korea, October 7,
2002.
47.
Topical retinoids in the treatment of extrinsically aged skin. Symposium on advances in
topical and oral retinoid therapy for the treatment of acne, psoriasis and extrinsically aged
skin. International Investigative Dermatology, Miami, USA, May 1, 2003
48.
Metabolism of retinoids in human skin in vivo. Asian Scientific Forum. International
Investigative Dermatology, Miami, USA, May 1, 2003
49.
Ultraviolet A1 is an effective antibiotic phototherapy for scleroderma, and sclerodermoid
variant of chronic graft-versus-host disease. International Investigative Dermatology,
Miami, USA, May 3, 2003
50.
Advances in intrinsic skin aging (Keynote lecture). 2003 International Federation of
Society of Cosmetic Chemist. Seoul, Korea, September 23, 2003
51.
Intrinsic skin aging and its treatment with retinol. Department of Dermatology, Seoul
National University, College of Medicine, Seoul, Korea, September 23, 2003
52.
Evidence for antioxidant usage in photoaging prevention. The 13th Japan-Korea Joint
Meeting of Dermatology, Daejeon, Korea, October 9, 2003
53.
Efficacy evaluation of anti-wrinkle products in the USA. International Symposium on
Efficacy and Safety of Anti-wrinkle Cosmetics. Korea Food & Drug Administration,
Seoul, Korea, November 7, 2003
54.
Advances in intrinsic skin aging. 18th Brazilian Cosmetology Congress, Sao Paulo,
Brazil, May 11, 2004
55.
UVA1 phototherapy for scleroderma. 10th Hamchun Dermatological Symposium, Seoul
National University, Seoul, Korea, June 9, 2004
56.
Photoprotection in the prevention of photoaging: study of mechanism. Symposium on
Photoprotection. 14th International Congress on Photobiology. Jeju, Korea, June 10-15,
2004
57.
Co-chair. Symposium on Photodermatology. 14th International Congress on
Photobiology. Jeju, Korea, June 10-15, 2004
58.
Photoaging pathophysiology. Department of Dermatology, Kosin University School of
Medicine, Busan, Korea, June 15, 2004
59.
Pathophysiology of photoaging. International Symposium on Cosmetic Laser Surgery,
Las Vegas, NV, September 10, 2004
60.
Immunopathogenesis of psoriasis. X Jornadas Dermatologicas de Clinica Alemana,
Santiago, Chile, October 1, 2004
61.
Sewon Kang, M.D.
Page 37
Retinoids: Pharmacology. X Jornadas Dermatologicas de Clinica Alemana, Santiago,
Chile, October 1, 2004
62.
Advances in our understanding of inflammatory acne. X Jornadas Dermatologicas de
Clinica Alemana, Santiago, Chile, October 2, 2004
63.
Photoaging pathophysiology. X Jornadas Dermatologicas de Clinica Alemana, Santiago,
Chile, October 2, 2004
64.
Topical retinoids and their effect on inflammatory mediators in acne. Dermatology
Update, 20th Anniversary, Vancouver, Canada, October 16, 2004
65.
New findings in inflammatory pathways and scar formation in acne. Symposium on
Recent Progress in Acne Management. 13th Congress of the European Academy of
Dermatology and Venereology. Florence, Italy, November 18, 2004
66.
Evidence for matrix remodeling in inflammatory acne (Invited Plenary Lecture). The
Korean Society for Acne Research. Seoul, Korea, March 5, 2005
67.
Advances in our understanding of inflammatory acne. Singapore Acne Symposium.
Singapore, March 31, 2005
68.
A new perspective in acne inflammation and its antagonism with retinoids (Invited
Plenary Lecture). Acne Symposium organized by Acne Task Force of the 7th Asian
Congress of Dermatology. Kuala Lumpur, Malaysia, April 1, 2005
69.
Scleroderma with special focus on UVA1 treatment (Invited lecture). Karolinska
Dermatology Symposium, Karolinska University Hospital, Stockholm, Sweden, April 15,
2005
70.
A new perspective in acne inflammation and its antagonism by retinoids (Invited lecture).
Asian Scientific Forum at the Society for Investigative Dermatology. St. Louis, MO,
May 6, 2005
71.
More to learn from Methotrexate. Reunión Anual de Dermatólogos latinoamaercanos.
Santiago, Chile, May 13, 2006
72.
Acne: What’s the lack of connection with psoriasis? Reunión Anual de Dermatólogos
latinoamaercanos. Santiago, Chile, May 13, 2006
73.
UVA1 for scleroderma. Reunión Anual de Dermatólogos latinoamaercanos. Santiago,
Chile, May 14, 2006
74.
Skin aging: Current concept. Reunión Anual de Dermatólogos latinoamaercanos.
Santiago, Chile, May 14, 2006
75.
Acne inflammation and matrix degradation. National Skin Center, Singapore, October
12, 2006
76.
Sewon Kang, M.D.
Page 38
Dermatologic research: excitement and challenges. National Skin Center, Singapore,
October 12, 2006
77.
Ultraviolet A1 phototherapy of scleroderma. National Skin Center, Singapore, October
13, 2006
78.
Pathophysiology & treatment of skin aging. Chapter of Dermatologists Lecture,
Singapore College of Physicians, Singapore, October 13, 2006
79.
Optimizing acne treatment with topical retinoid: based on pathophysiology and clinical
evidence. The 70th Annual Meeting of the Tokyo Division of Japanese Dermatological
Association, Tokyo, February 17, 2007
80.
Mechanical tension and fibroblast function: lessons learned from cross-linked hyaluronic
acid filler injections into photoaged human skin. Department of Dermatology, Asan
Medical Center, Seoul, Korea, April 11, 2007.
81.
Photoaging prevention by a soy extract genistein. Kyung Hee University, College of
Oriental Medicine, Seoul, Korea, April 13, 2007.
82.
Retinoids in prevention and therapy of photoaging. Symposium on The Aging Skin, The
16th Congress of the European Academy of Dermatology and Venereology, Vienna,
Austria, May 18, 2007.
83.
New approaches to retinoid therapy. Symposium “Dermatotherapy- The classics”, The
21st World Congress of Dermatology, Buenos Aires, Argentina, October 1, 2007.
84.
New perspectives in acne inflammation. Satellite Symposium “Facing the future:
unconventional approaches to acne management”, 21st World Congress of Dermatology,
Buenos Aires, Argentina, October 3, 2007
85.
Does enough evidence now exist for using lasers and other procedures to treat acne?
Satellite Symposium “Facing the future: unconventional approaches to acne
management”, 21st World Congress of Dermatology, Buenos Aires, Argentina, October
3, 2007
86.
Inflammatory pathways that lead to scarring. Meeting of Minds “ Inflammatory acne:
can we prevent/reduce scarring?”, 21st World Congress of Dermatology, Buenos Aires,
Argentina, October 5, 2007
87.
Skin of color: teaching us to be better clinicians/investigators. The L’Oreal Institute for
Ethnic Hair & Skin Research: 4th International Symposium, Miami, FL November 10,
2007.
88.
Retinoid signaling in human skin in vivo. Symposium on Advances in Acne – global
impact, pathogenesis, treatment & research. International Investigative Dermatology
2008, Kyoto, Japan, May 14, 2008.
89.
Acne and dermal tissue. Sebaceous gland, acne, rosacea and related disorders: Basic and
clinical research, clinical entities and treatment. Rome, Italy, September 14, 2008.
Sewon Kang, M.D.
Page 39
90.
Inflammation and scar formation in acne. 8th Asian Dermatological Congress. Seoul,
Korea, October 1, 2008.
91.
Advances in photoaging: an inside-out to outside-in story (Invited Plenary Lecture). 8th
Asian Dermatological Congress. Seoul, Korea, October 2, 2008.
92.
Mode of action of retinoids in acne. 8th Asian Dermatological Congress. Seoul, Korea,
October 2, 2008.
93.
Are there effective treatments for photoaging? 10th International Congress of
Dermatology, Prague, Czech Republic, May 22, 2009
94.
What’s new in the pathophysiology of photoaging. XXVI – RADLA, Mexico City,
Mexico, July 7, 2009.
95.
Dermatology residency training in the USA: Johns Hopkins experience. Department of
Dermatology, Seoul Asan Medical Center. Seoul, Korea, November 9, 2009.
96.
Mechanism of action of treatment modalities for photoaging. The 5th Annual Meeting of
the Chinese Dermatologists Association. Suzhou, China. November 11, 2009.
97.
Pathophysiology of photoaging. The 5th Annual Meeting of the Clinical Dermatologist
Association. Suzhou, China, November 13, 2009.
98.
Improving photoaged skin with lasers, dermabrasions and topical 5-FU: in search of an
unifying principle. (Plenary Lecture 1). The 20th Academic Meeting of Korean Society
for Investigative Dermatology. Seoul, Korea. April 2, 2010
99.
Harnessing ultraviolet light to improve skin fibrosis. (Plenary Lecture 2). The 20th
Academic Meeting of Korean Society for Investigative Dermatology. Seoul, Korea.
April 3, 2010
100.
Retinoid Pharmacology in Dermatology: Mechanism of action of adapalene.
Symposium on Adaferin. Mexico City, Mexico. August 26, 2010
101.
Applying Computer Technology to Dermatology: Tracking of acne lesions. The First
Eastern Asia Dermatology Congress. Fukuoka, Japan. October 1, 2010
102.
Skin Photaging: From the outside in. (Keynote Lecture) Symposium of the European
Society for Photodermatology. 19th Congress of the European Academy of Dermatology
and Venereology. Gothenburg, Sweden. October 6, 2010
103.
Smoking and skin aging: additional associations. Korean Society for Investigative
Dermatology. 22nd World Congress of Dermatology. Seoul, Korea. May 24, 2011.
104.
Natural history of acne lesions: lessons learned from computer image processing. Acne
World – Clinical and Laboratory Update in Acne. 22nd World Congress of Dermatology,
Seoul, Korea. May 24, 2011.
105.
Sewon Kang, M.D.
Page 40
Topical retinoids for skin aging. 22nd World Congress of Dermatology. Seoul, Korea.
May 25, 2011.
106.
Skin aging: interplay between cells and the dermal matrix. 22nd World Congress of
Dermatology, Seoul, Korea. May 25, 2011.
107.
Skin aging in Asians: Factors to consider in pathophysiology & treatment options. 22nd
World Congress of Dermatology, Seoul, Korea. May 25, 2011.
108.
Acne sequelae and its consequences. 22nd World Congress of Dermatology, Seoul, Korea.
May 26, 2011.
109.
Acne. What’s New? 22nd World Congress of Dermatology, Seoul, Korea. May 28, 2011.
110.
Retinoids for anti-aging. 10th International Congress of International Society of Cosmetic
Dermatology. Shenyang, China. May 31, 2011.
111.
Understanding the stratum corneum and molecular mechanisms involved in retinoid
dermatitis. 10th International Congress of International Society of Cosmetic
Dermatology. Shenyang, China. May 31, 2011.
112.
Repair of photoaged skin: a unifying concept. Symposium on photoaging mechanisms
and reversal. European Society for Photobiology. Geneva, Switzerland. September 5,
2011.
113.
New insights on acne scarring and implications for your clinical practice. European
Academy of Dermatology and Venereology. Lisbon, Portugal. October 23, 2011.
114.
Acne – Inflammatory cascade involving innate immune system. IX Congress Bienal De
Dermatologia, Puerto Vallarta, Mexico. November 19, 2011.
115.
Photoaging pathophysicology. IX Congress Bienal De Dermatologia, Puerto Vallarta,
Mexico. November 19, 2011.
116.
Solar scarring: Basis for premature skin aging & implications for the eye. King Khaled
Eye Specialist Hospital (KKESH), Riyadh, Saudi Arabia. April 4, 2012.
117.
What’s new in acne pathophysiology. CILAD, Seville, Spain, September 20, 2012
118.
Acne scarring pathophysiology. CILAD, Seville, Spain, September 21, 2012
119.
Acne sequelae and its consequences. CILAD, Seville, Spain, September 21, 2012
120.
Chipping away at acne scars: Pathogenesis, treatment and prevention. Asia Pacific Acne
Symposium (APAS), Seoul, Korea, October 6, 2012
121.
Evidence-based therapeutic strategy for the prevention of acne scars. The 37th Annual
Meeting of the Japanese Society for Investigative Dermatology, Okinawa, Japan,
December 7, 2012.
122.
Sewon Kang, M.D.
Page 41
Perioral wrinkling and its association with photoaging. Department of Dermatology,
Seoul National University College of Medicine, Seoul, Korea, February 15, 2013.
123.
Differential effects of solar radiation (UVB, UVA1 and IR) on light and dark human
skin: implications on photoaging. Institute of Human Environment Interface Biology,
Seoul National University College of Medicine, Seoul, Korea, February 16, 2013.
124.
Acne scarring: pathogenesis, treatment and prevention. Kosin University College of
Medicine, Busan, Korea, April 19, 2013.
125.
Acne scars: pathogenesis, prevention and treatment. (Plenary lecture). 9th Asian
Dermatological Congress, Hong Kong, China, July 11, 2013.
126.
Acne Sequelae (scarring & PIH). 9th Asian Dermatological Congress, Hong Kong,
China, July 12, 2013.
127.
Antiaging cosmeceuticals: rationale & reality. 9th Asian Dermatological Congress, Hong
Kong, China, July 13, 2013.
128.
Molecular understanding of retinoid dermatitis and ways to minimize it. 9th Asian
Dermatological Congress, Hong Kong, China, July 13, 2013.
129.
Acne scar: pathogenesis and prevention. 39th Annual Meeting of the Taiwanese
Dermatological Association, Taipei, Taiwan, November 16, 2013.
130.
Acne sequalae. 39th Annual Meeting of the Taiwanese Dermatological Association,
Taipei, Taiwan, November 17, 2013.
131.
Photoaging pathogenesis and prevention. The 12th International GCC Dermatology
Venereology and Laser Conference, Kuwait City, Kuwait, November 20, 2013.
132.
UVA1 phototherapy of scleroderma/morphea. The 12th International GCC Dermatology
Venereology and Laser Conference, Kuwait City, Kuwait, November 20, 2013.
133.
Acne scar pathogenesis. The 12th International GCC Dermatology Venereology and Laser
Conference, Kuwait City, Kuwait, November 21, 2013.
PRESENTATIONS: NATIONAL
1.
Etretinate therapy for psoriasis inhibits both serum chemotaxis for and cytolytic activity
by neutrophils. National Clinical Dermatology Conference, Chicago, June, 1983
2.
Improvement in glucose tolerance and insulin sensitivity during etretinate therapy for
psoriasis. American Academy of Dermatology Summer Session, San Diego, June, 1985
3.
Report on Midwest Student Medical Research Forum XVII to the American Medical
Association - Education Research Foundation Council, National Student Research
Forum, Galveston, April, 1986
4.
Sewon Kang, M.D.
Page 42
Phenotype and antigen presenting cell function of murine dermal cells. National Student
Research Forum, Galveston, April, 1987
5.
Multiple primary melanoma: implications in patient management. American Federation
for Clinical Research Joint Subspecialty Meeting, Washington DC, May 1990
6.
Retinoids improve granulomatous dermatitis. American Academy of Dermatology,
Atlanta, December, 1990
7.
Clinical characterization of psoriatic plaques in vivo using digital microscopy. American
Academy of Dermatology, Atlanta, December, 1990
8.
In vivo characterization of pigment patterns in dysplastic nevi using digital
epiluminescence microscopy. American Academy of Dermatology, Atlanta, December,
1990
9.
Histologic regression in malignant melanoma: an interobserver concordance study.
American Society of Dermatopathology, Atlanta, November, 1990
10.
Melanoma and melanoma precursors - pigment pattern characterization in vivo using
computer-assisted epiluminescence microscopy. American Society of
Dermatopathology, Atlanta, November, 1990
11.
Melanoma risk is increased in patients with atypical nevi even with close follow-ups.
Society for Investigative Dermatology, Seattle, May, 1991
12.
Digital epiluminescence microscopy (Digital ELM) - a noninvasive tool for improving
the differential diagnosis of pigmented lesions. American Academy of Dermatology,
Dallas, December 1991
13.
Identification of the skin phototype - new data on self-reporting versus interview.
Photobiology: science and clinical practice (Course 206). American Academy of
Dermatology, Dallas, December, 1991
14.
Digital Epiluminescence Microscopy: Massachusetts General Hospital Experience.
Strategies in the Early Detection and Prevention of Melanoma (Forum 519). American
Academy of Dermatology, Dallas, December, 1991
15.
Class II MHC+ cells in the dermis exhibit the phenotypic, ultrastructural and functional
characteristics of dermal Langerhans cells. Society for Investigative Dermatology,
Baltimore, April, 1992
16.
Grading protocol for clinical diganosis of pigmented lesions using digital
epiluminescence microscopy. American Society of Dermatopathology, San Francisco,
December 1992
17.
Update on digital epiluminescence microscopy. American Academy of Dermatology,
San Francisco, December 1992
18.
Sewon Kang, M.D.
Page 43
Topical retinol induces CRABP-II mRNA expression and epidermal hyperplasia but only
trace erythema in human skin in vivo. Society for Investigative Dermatology,
Washington DC, April 1993
19.
Tumor vascularity as a prognostic factor in cutaneous malignant melanoma. Society for
Investigative Dermatology, Washington DC, April 1993
20.
Early detection of melanoma by visualizing perturbations of pigment network
morphology using digital epiluminescence microscopy. American Academy of
Dermatology, Washington DC, December 1993
21.
Metabolism of retinoids in skin. Retinoid Symposium. American Academy of
Dermatology, Washington D.C., December, 1993
22.
Topical retinol increases retinyl ester but not retinoic acid content and enhances
expression of cellular retinol binding protein mRNA and protein in normal human skin in
vivo. Society for Investigative Dermatology, Baltimore MD, April 1994
23.
All-trans, 9-cis, 13-cis retinoic acid each induce a Cytochrome P-450 4-retinoic acid
hydroxylase which causes all-trans but not 9-cis or 13-cis retinoic acid to selfmetabolize. Society for Investigative Dermatology, Baltimore MD, April 1994
24.
Topical retinol increases retinyl-ester but not retinoic acid content and enhances
expression of CRBP mRNA and protein in normal human skin in-vivo. FASEB Summer
Research Conference on Retinoids, Copper Mountain, Colorado, June 1994
25.
The utility of prolonged occlusion in the treatment of psoriasis. Psoriasis Symposium,
Chicago IL, July 1994
26.
Topical tretinoin improves systemic steroid-induced striae distensae. American Academy
of Dermatology, New Orleans, February, 1995
27.
Liarozole plus retinol application increases human skin retinoic acid levels producing a
typical retinoid response without irritation. Society for Investigative Dermatology,
Chicago IL, May 1995
28.
Ultraviolet irradiation rapidly up regulates transcription factors AP-1 and NF-kB and
subsequently induces expression of target genes for matrix-degrading metalloproteinases
in human skin in-vivo. Society for Investigative Dermatology, Chicago IL, May, 1995
29.
Metabolism of retinoids in human skin. Focus Session. American Academy of
Dermatology, Washington D.C., February, 1996
30.
Retinoid-X-receptor ligand 9-cis retinoic acid synergistically enhances the activation of
vitamin D-responsive 24-hydroxylase gene by 1,25(OH)2D3 in human skin in-vivo.
Keystone Symposia on Molecular and Cellular Biology: Sterioid/Thyroid/Retinoic Acid
Gene Family, Lake Tahoe, CA, March, 1996
31.
Activation of the vitamin D-responsive 24-hydroxylase gene by 1,25(OH)2D3 is
synergistically enhanced by retinoid-X receptor ligand 9-cis retinoic acid and by the 24-
Sewon Kang, M.D.
Page 44
hydroxylase inhibitor ketoconazole in human skin in-vivo. Society for Investigative
Dermatology (for the General Plenary Session), Washington DC, May 1996
32.
RXR agonists or 24-hydroxylase inhibitors increase the activity of vitamin D3. FASEB
Summer Research Conference on Retinoids, Copper Mountain, Colorado, June 1996
33.
Dermatopharmacology of vitamins A and D. American Academy of Dermatology,
Academy ‘96, Orlando, July 1996
34.
Basic Immunopathogenesis of psoriasis. New England Dermatological Society and
National Psoriasis Foundation Symposium on Psoriasis, Boston, November, 1996
35.
Metabolism of retinoids in human skin: Focus session. American Academy of
Dermatology, San Francisco, March 1997
36.
Retinoid/steroid nuclear receptors in skin - how do they work. American Academy of
Dermatology, San Francisco, March 1997
37.
Tretinoin therapy of striae. The Evolving Role of Retinoids in the Management of
Cutaneous Conditions. Cleveland Clinic Foundation. New York, NY, May 1997
38.
Metabolism and molecular action of vitamin D3 and its analogs. University of Chicago,
Chicago, Illinois, July 1997
39.
Retinoids-Past, Present, Future. Symposium on current concepts in acne and rosacea.
Academy ‘97, New York, July 1997
40.
Skin pharmacology of vitamins A and D. Academy ‘97, New York, August 1997
41.
Deltanoids. New therapeutic approaches for psoriasis. Academy ‘97, New York, August
1997
42.
Retinoid dermatitis: its molecular basis and clinical implications. Buffalo/Rochester
Dermatology Society, Rochester, New York, October, 1997
43.
Vitamin D3 metabolism and action in human skin in-vivo. University of Rochester,
Strong Memorial Hospital, Rochester, New York, October, 1997
44.
Retinoid metabolism in human skin. American Academy of Dermatology, Orlando,
March, 1998
45.
Immunosuppressive drugs for dermatology. American Academy of Dermatology,
Orlando, March, 1998
46.
Molecular basis of retinoid effects on photoaging (Invited lecturer). Twenty-sixth
Annual Meeting of the American Society for Photobiology, Snowbird, Utah, July 1998
47.
Management of photoaging. Symposium on Sun Protection & Photodamage: New
Insight. Academy ‘98, Chicago, July, 1998
48.
Sewon Kang, M.D.
Page 45
Retinoids & deltanoids in skin pharmacology. Academy ‘98, Chicago, August, 1998
49.
Psoriasis as an autoimmune disease: Novel therapeutic approaches. Academy ‘98,
Chicago, August, 1998
50.
Molecular mechanism of tretinoin in photoaging. American Academy of Dermatology,
New Orleans, March, 1999
51.
Retinoids: Understanding its mechanism of action. American Academy of Dermatology,
New Orleans, March, 1999
52.
Immunosuppressive drugs for dermatology. American Academy of Dermatology, New
Orleans, March, 1999
53.
The antioxidant N-acetyl cysteine increases the content of the endogenous antioxidant
glutathione and prevents UV-induction of matrix metalloproteinases in human skin in
vivo. Society for Investigative Dermatology, Chicago, May, 1999
54.
Psoriasis- An immunologic disease. Annual Meeting of the Massachusetts Academy of
Dermatology, North Falmouth, October, 1999
55.
Therapeutic update in atopic dermatitis. Annual Meeting of the Massachusetts Academy
of Dermatology, North Falmouth, October, 1999
56.
Understanding the side-effect of topical retinoids. American Academy of Dermatology,
San Francisco, March, 2000
57.
Understanding the cutaneous side effects of topical tretinoin. Symposium on Photoaging
and Intrinsic Aging of the Skin, Academy 2000, Nashville, August, 2000
58.
What are barriers to conducting clinical research in dermatology. Annual Meeting of
Professors of Dermatology, Inc., Chicago, September, 2000
59.
Ultraviolet A1 phototherapy for scleroderma. National Institute of Health, National
Cancer Institute, Dermatology Branch, Bethesda, February, 2001
60.
Photoaging pathophysiology, treatment and prevention. Department of Dermatology,
University of Pittsburgh, Pittsburgh, February, 2001
61.
The role of metalloproteinases in acne. A Symposium on Advances in Acne Research,
Society for Investigative Dermatology, Washington, DC, May, 2001
62.
Antioxidants for photoaging prevention. Photoprotection Symposium. 29th Annual
Meeting of the American Society for Photobiology, Chicago, July, 2001
63.
The physiologic and pharmacologic action of retinoid receptors. Visiting Professor
Program, Center for Drug Evaluation and Research, U.S. Food and Drug Administration,
Rockville, MD, July 19, 2001
64.
Sewon Kang, M.D.
Page 46
Latest finding for retinoids in photodamage. Symposium on Innovations in Improving
Facial Appearance. Academy 2001, Annaheim, CA, July, 2001
65.
Elucidating the pathophysiologic mechanism of photoaging in vivo. The 10th Annual R.
William Gange Lecturer. The Wellman Laboratories of Photomedicine, Massachusetts
General Hospital, Boston, MA, November 27, 2001
66.
Psoriasis. Poster discussion session moderator. American Academy of Dermatology,
New Orleans, LA, February, 2002.
67.
Pathophysiology and the treatment of photodamage. Valley of the Sun Conference on
Clinical Dermatology, Scottsdale, AZ, April 28, 2002.
68.
Retinol, retinoic acid, retinyl esters... what’s the difference? Valley of the Sun
Conference on Clinical Dermatology, Scottsdale, AZ, April 28, 2002.
69.
Matrix alterations in skin aging and retinoid antagonism. 2nd Annual Aging Skin
Conference, University of Minnesota, Minneapolis, MN, May 3, 2002.
70.
Symposium chair – Photodamage: pathogenesis, manifestations, prevention, and
treatment. Academy 2002, New York, NY, July 31, 2002.
71.
Recent advances in photoaging. Academy 2002, New York, NY, August 3, 2002.
72.
Retinol: a retinoid. 1st Annual meeting of the American Society of Cosmetic
Dermatology & Aesthetic Surgery, Las Vegas, NV, December 8, 2002.
73.
Pharmacologic dissection of psoriasis. Winter Skin Seminar, Snowmass, CO, February
3, 2003
74.
New concept in acne scarring. Winter Skin Seminar, Snowmass, CO, February 4, 2003
75.
Histologic evaluation of photoaged skin. Symposium on photoaging. Hawaii
Dermatology Seminar, Maui, February 16, 2003
76.
Clinical Research in Dermatology. National Institute of Arthritis Musculoskeletal and
Skin Diseases, National Institutes of Health, Bethesda, MD, March 3, 2003
77.
A mechanism of matrix destruction in inflammatory acne. Skin Disease Research Center,
Department of Dermatology, Case Western University School of Medicine, Cleveland,
OH, March 13, 2003
78.
New topical immunomodulators for atopic dermatitis. American Academy of
Dermatology, San Francisco, CA, March 22, 2003
79.
Photoaging. Valley of the Sun Conference on Clinical Dermatology, Scottsdale, AZ,
May 18, 2003
80.
Antioxidants and photoaging. Photoaging & Photoprotection Symposium. The 31st
Annual Meeting of the American Society for Photobiology, Baltimore, MD, July 7, 2003
Sewon Kang, M.D.
Page 47
81.
Current perspective on acne inflammation and scarring. Symposium on Improving the
treatment of inflammatory acne. Academy ’03, Chicago, IL, July 25, 2003
82.
Scleroderma & phototherapy. Academy ’03, Chicago, IL, July 28, 2003
83.
New perspective on the pathogenesis of acne: focus on understanding inflammatory
pathways. American Academy of Dermatology, Washington DC, February 7, 2004
84.
Scleroderma & phototherapy. American Academy of Dermatology, Washington DC,
February 10, 2004
85.
Immunopharmacology of psoriasis. Movitz Visiting Professor in Psoriasis, University of
Utah, Department of Dermatology, Salt Lake City, Utah, February 27, 2004
86.
Learning dermatology/medical science from psoriasis patients. Movitz Visiting Professor
in Psoriasis, University of Utah, Department of Dermatology, Salt Lake City, Utah,
February, 27, 2004
87.
Treatment-Directed Pathophysiology. DF: Clinical Symposia Advances in Dermatology,
Amelia Island, Florida, March 18, 2004
88.
Retinoids. DF: Clinical Symposia Advances in Dermatology, Amelia Island, Florida,
March 20, 2004
89.
Anti-Inflammatory Effects of Retinoids. DF: Clinical Symposia Advances in
Dermatology, Amelia Island, Florida, March 20, 2004
90.
Co-chair. Symposium on Photoprotection and Photoaging. 32nd Annual Meeting of the
American Society for Photobiology. Seattle, Washington, July 12, 2004
91.
Update on antioxidants in photoaging. 32nd Annual Meeting of the American Society for
Photobiology. Seattle, Washington, July 12, 2004
92.
Photoaging and skin of color. Academy ’04, New York, New York, July 31, 2004
93.
Actinic keratoses and photodamage: Clinical experience with topical retinoids.
Symposium in Expanding the Therapeutic Horizon for Topical Retinoids. Academy ’04,
New York, New York, July 31, 2004
94.
UVA1 phototherapy of scleroderma. Department of Dermatology, Oregon Health &
Science University, Portland, Oregon, August 13, 2004
95.
Photoaging pathophysiology. Oregon Dermatology Society Annual Meeting, Sunriver,
Oregon, August 14, 2004
96.
New concept in acne inflammation. Oregon Dermatology Society Annual Meeting,
Sunriver, Oregon, August 15, 2004
97.
Sewon Kang, M.D.
Page 48
Molecular aspects of photodamage and retinoid therapy. Avon at Penn meeting,
Philadelphia, Pennsylvania, October 15, 2004
98.
UVA1 phototherapy of scleroderma. Department of Dermatology, UCLA, Los Angeles,
December 21, 2004
99.
Photoaging: pathogenesis, treatment and prevention. Division of Dermatology,
University of California San Diego, Feb 10, 2005
100.
Scleroderma & phototherapy. American Academy of Dermatology, New Orleans, LA,
February 19, 2005
101.
Update on antioxidants in photoaging. American Academy of Dermatology, New
Orleans, LA, February 20, 2005
102.
Induction of matrix metalloproteinases and inhibition of procollagen synthesis in human
skin in vivo by ultraviolet A1 irradiation is profoundly diminished by skin pigmentation.
American Academy of Dermatology, New Orleans, LA, February 20, 2005
103.
Introductory lecture to minisymposium on Clinical Research and Therapeutics. Society
for Investigative Dermatology, St. Louis, MO, May 5, 2005
104.
How a soy extract genistein affects UV inflammation. Symposium on advancing the
science of naturals, Academy ’05, Chicago, Illinois, July 22, 2005
105.
Antioxidants and prevention of photoaging. Seminar in advances in photoprotection and
photoaging, Academy ’05, Chicago, Illinois, July 23, 2005
106.
Ultraviolet-A1 phototherapy of scleroderma. 125th Annual Meeting of the American
Dermatological Association, Greensboro, GA, September 15, 2005.
107.
Pathophysiology of photoaging. Department of Dermatology, SUNY Downstate Medical
Center, Brooklyn, NY, September 21, 2005.
108.
UVA1 phototherapy of scleroderma. Department of Dermatology, SUNY Downstate
Medical Center, Brooklyn, NY, September 21, 2005.
109.
Basics of skin photodamage and aging. SID Basics of Skin: Pharmaceutics and
Pharmacology course. San Antonio, TX, October 7, 2005.
110.
Aging workshop. SID Basics of Skin: Pharmaceutics and Pharmacology course. San
Antonio, TX, October 7, 2005.
111.
UVA1 and scleroderma. Brooke Army Medical Center, San Antonio, TX, February 2,
2006.
112.
Acne inflammation. Brooke Army Medical Center, San Antonio, TX, February 2, 2006.
113.
Rationale for the use of antioxidants in photoaging prevention. Advanced Technology
Conference America, Miami, FL, February 6, 2006.
Sewon Kang, M.D.
Page 49
114.
Scleroderma and phototherapy. American Academy of Dermatology, San Francisco, CA,
March 4, 2006.
115.
Evidence for matrix degradation in inflammatory acne. Department of Dermatology,
Stanford School of Medicine, Palo Alto, CA, March 20, 2006.
116.
Mechanisms of action of drugs in acne. Valley of the Sun Conference, Phoenix, AZ,
April 1, 2006.
117.
Inflammatory acne and matrix remodeling. Symposium on Advances in Acne Research,
Society for Investigative Dermatology, Philadelphia, PA, May 3, 2006.
118.
The role of retinoids in preventing and treating skin aging changes. The 35th Annual
Meeting of the American Aging Association, Boston, MA, June 4, 2006.
119.
Advances in the pathophysiology of photoaging. Academy ’06, San Diego, CA, July 27,
2006.
120.
Effects of UV in pigmented human skin. Academy ’06, San Diego, CA, July 27, 2006.
121.
Basics of skin and aging. SID Basics of Skin: Pharmaceutics and Pharmacology course.
San Diego, CA, October 20, 2006.
122.
Aging workshop. SID Basics of Skin: Pharmaceutics and Pharmacology course. San
Diego, CA, October 20, 2006.
123.
Inflammation and matrix remodeling in acne. Skin Disease Research Center, University
of Alabama, Birmingham, AL, December 6, 2006.
124.
Scleroderma and phototherapy. American Academy of Dermatology, Washington DC,
February 5, 2007.
125.
Photoaging – how does the sun make us look old? And what are the topical strategies for
treatment? American Academy of Dermatology, Washington DC, February 5, 2007.
126.
Harnessing UV light to improve skin fibrosis. Khosrow Momtaz, MD Memorial Lecture,
Harvard Medical School, Department of Dermatology, Massachusetts General Hospital,
Boston, MA, March 1, 2007.
127.
Skin aging. SID Basics of Skin: Pharmaceutics and Pharmacology course. Miami, FL
December 7, 2007
128.
Retinoids & Antioxidants. SID Basics of Skin: Pharmaceutics and Pharmacology course.
Miami, FL December 7, 2007
129.
Computer- assisted alignment and tracking of acne lesions. The 3rd Annual Meeting of
the American Acne & Rosacea Society. San Antonio, TX, February 1, 2008.
130.
Sewon Kang, M.D.
Page 50
Photaging- how does the sun make us look old? And what are the topical strategies for
treatment? American Academy of Dermatology, San Antonio, TX, February 1, 2008.
131.
Update on acne scarring. American Academy of Dermatology, San Antonio, TX,
February 2, 2008.
132.
Understanding topical retinoids’ effects & side-effects. American Academy of
Dermatology, February 5, 2008.
133.
Evidence-based therapy of scleroderma with UVA-1. Department of Dermatology,
University of Texas Southwestern Medical Center, Dallas, TX, June 19, 2008.
134.
The Pharmacology of retinoids in human skin. Symposium on the changing the face of
acne therapy, Academy ’08, Chicago, IL, August 1, 2008.
135.
Natural skin aging and topical retinol: pathogenesis & potential therapy. Duhring
Lectureship, Department of Dermatology, University of Pennsylvania School of
Medicine. Philadelphia, PA, December 4, 2008.
136.
Update on photoaging. 86th Atlantic Dermatological Conference. Baltimore, MD, April
3, 2009.
137.
Topical 5-FU Improves Photoaging Society for Investigative Dermatology, Montreal,
Canada. May 7, 2009.
138.
How sun makes you look old. The 26th Annual Convention and Scientific Meeting of the
Seoul National University College of Medicine Alumni Association of America,
Dearborn, MI, July 6, 2009.
139.
Photoaging: topical drugs (retinoids). 129th Annual Meeting of the American
Dermatological Association, Park City, Utah, August 20, 2009.
140.
Photoaging. Henry Menn Memorial lecture, The 36th annual Meeting of the Masters
Dermatologic Association, Pinehurst, North Carolina. October 20, 2009.
141.
Retinoid pharmacology in human skin. Department of Dermatology, University of
Cincinnati, Cincinnati, Ohio. December 2, 2009.
142.
Photoaging pathophysiology. Cincinnati Dermatological Society, Cincinnati, Ohio.
December 2, 2009.
143.
UVA-1 phototherapy of scleroderma. Cincinnati Dermatological Society, Cincinnati,
Ohio. December 3, 2009.
144.
Retinoid pharmacology in human skin in vivo. Department of Dermatology, Albert
Einstein College of Medicine, Yeshiva University, Bronx, New York. December 17,
2009.
145.
Retinoid pharmacology relevant in acne. Maui Dermatology Meeting, Maui, Hawaii.
January 25, 2010.
Sewon Kang, M.D.
Page 51
146.
Acne inflammation and scarring. Department of Dermatology, New York University
School of Medicine, New York, NY. February 12,2010.
147.
Update on pathogenesis of acne. American Academy of Dermatology, Miami, FL.
March 5, 2010.
148.
Understanding topical retinoids’ effects and side effects. American Academy of
Dermatology, Miami, FL. March 9, 2010.
149.
The burden of skin cancer in the U.S. The open Public Hearing, FDA Advisory
Committee Meetings, Gaithersburg, MD, March 25, 2010.
150.
Finding your ideal field in medicine. APAMSA 2010 National Conference. Baltimore,
MD. October 16, 2010
151.
Skin Pigmentation and the induction of Matrix metalloproteinases by UV. National
Institutes of Health, National Cancer Institute, Bethesda, MD June 22, 2012.
152.
Photoaging in skin of color. National Medical Association. Bethesda, MD. July 25,
2011.
153.
Skin in space. National Space Biomedical Research Institute (NSBRI) and National
Aeronautics and Space Administration (NASA), Webinar. March 19, 2013.
154.
Differential effects of solar radiation on light and dark skin: implications in photoaging.
Skin Disease Research Center, Department of Dermatology, Case Western Reserve
University, Cleveland, Ohio. April 25, 2013
155.
Repair of photoaged skin: a unifying concept. Department of Dermatology, Weill
Cornell Medical College, New York, New York. May 31, 2013
156.
How does skin color influence photoaging. The 11th Annual Young C. Kauh, MD
Clinical Dermatology Lectureship, Department of Dermatology & Cutaneous Biology,
Jefferson Medical College, Philadelphia, PA. October 24, 2013
PRESENTATIONS: LOCAL AND REGIONAL
1.
Etretinate therapy for psoriasis inhibits both serum chemotaxis and cytolytic activity by
neutrophils. University of Michigan Student Medical Research Forum, Ann Arbor,
October, 1983
2.
Immunologic effects of etretinate therapy for psoriasis. XVth Midwest Student Medical
Research Forum, Madison, March, 1984
3.
Etretinate therapy enhances glucose metabolism. University of Michigan Student
Medical Research Forum, Ann Arbor, October, 1984
4.
Sewon Kang, M.D.
Page 52
Glucose metabolism during etretinate administration. XVth Midwest Student Medical
Research Forum, Dayton, March, 1985
5.
Retinoids: Can a hyperlipidemic agent treat diabetes? Michigan Diabetes and Research
and Training Center. Workshop on Complications of Diabetes, Ann Arbor, June, 1985
6.
Phenotypic and functional study on dermal antigen presenting cells in mouse. Midwest
Student Research Forum XVIII, Louisville, February, 1987
7.
Our maturing skin. Lurie Terrace Senior Citizens Housing Inc., Ann Arbor, January,
1993
8.
Sun-induced skin problems. Family Practice Spring Review, University of Michigan
Medical Center, Ann Arbor, March, 1993
9.
New perspectives in antifungal therapy. The 96th Annual Convention of the Indiana
Association of Osteopathic Physicians and Surgeons, Indianapolis, May 1993
10.
Selected common dermatoses - diagnosis and treatment. University of Michigan Internal
Medicine Noon Conference, Ann Arbor, April 1994
11.
Metabolism of retinoids in human skin. The Michigan Dermatological Society, Ann
Arbor, March 1995
12.
Cutaneous manifestations of HIV infection. Invited Speaker at the Twelfth Annual
Meeting of the Korean-American Medical Association of Michigan, Bay City, Michigan,
May 1995
13.
A view from clinical pharmacology unit. Psoriasis symposium at the Michigan
Dermatological Society, Ann Arbor, March 1996
14.
The importance of aging skin research. Lurie Terrace Senior Citizens Housing Inc., Ann
Arbor, September, 1996
15.
Clinical management of acne vulgaris - rationale for topical retinoids. Broward County
Dermatology Society Meeting, Florida, February, 1997
16.
Retinoic acid therapy of skin diseases. Michigan Dermatological Society Meeting, Ann
Arbor, February, 1998
17.
Ultraviolet A1 for the treatment of scleroderma: bad news from photoaging turned good.
University of Michigan, Rackham Arthritis Research Unit Seminar Series, Ann Arbor,
February, 2000
18.
Ultraviolet A1 phototherapy for scleroderma. Michigan Dermatological Society, Ann
Arbor, February, 2000
19.
Treating scleroderma with UVA1. Dermatology Sesquicentennial Grand Rounds, Ann
Arbor, October, 2000
20.
Sewon Kang, M.D.
Page 53
Skin photoaging– elucidating its pathophysiology. Korean-American Medical
Association of Michigan Scientific Seminar, Mt. Pleasant, Michigan, May, 2001
21.
Immunopharmacology of psoriasis. University of Michigan Medical Center, General
Clinical Research Center Seminar Series, Ann Arbor, June, 2001
22.
New Views on Acne. Michigan Dermatological Society, Ann Arbor, March, 2002
23.
Ultraviolet A1 phototherapy for sclerodermoid graft versus host disease. Seminar in
Bone Marrow Transplant Service, University of Michigan Health System, Ann Arbor,
March, 2002
24.
Photoaging science update for the practitioner. The 11th Annual Dermatology Visiting
Professor Program. NEOUCOM, Cleveland, Ohio, November, 2002
25.
UVA1 Phototherapy of scleroderma: an update. Seminar at the Rackham Arthritis
Research Unit, Division of Rheumatology, University of Michigan Health System, Ann
Arbor, January 15, 2003
26.
Advances in acne therapy. The University of Michigan Student Health Service
Continuing Medical Education Program. Ann Arbor, February 20, 2003
27.
Photoaging pathophysiology. Department of Dermatology, Wayne State University
School of Medicine. Detroit, March 5, 2003
28.
Immunopathophysiology of psoriasis. Department of Dermatology, Henry Ford Health
System, West Bloomfield, June 7, 2003
29.
Update on acne and rosacea. Multidisciplinary Conference, Flower Hospital, Sylvania,
Ohio, February 24, 2004
30.
Cutaneous manifestation of internal diseases. Grand Rounds Department of Family
Medicine, University of Michigan, February 25, 2004
31.
Clinical Pharmacology Unit. Dermatology Dialouges, Department of Dermatology,
University of Michigan, April 13, 2004
32.
Softening the Skin of Scleroderma with Phototherapy. Scleroderma Foundation,
Michigan Chapter, Patient Education Seminar, University of Michigan, October 10, 2004
33.
Photoaging: pathogenesis, treatment and prevention. Michigan Center for Oral Health
Research, The 1st Research Seminar. University of Michigan, School of Dentistry,
January 19, 2005
34.
UVA1 Update. Michigan Dermatological Society, Ann Arbor, April 6, 2005
35.
How the summer research program shaped my career path. Student Biomedical Fall
Research Forum, Ann Arbor, November 2, 2006
36.
Sewon Kang, M.D.
Page 54
Retinol treatment of naturally aged skin. Michigan Dermatological Society, Ann Arbor ,
April 30, 2008
37.
UVA-1 photography of scleroderma. Maryland Dermatological Society, Johns Hopkins
Medicine, Baltimore, Maryland, November 6, 2008.
38.
Skin deep. A Women’s Journey, Johns Hopkins Medicine, Palm Beach, Florida, January
22, 2009.
39.
Dermatology for the internist. 12th Annual Johns Hopkins Internal Medicine Board
Review. Baltimore, MD, July 15, 2009.
40.
New insights into acne inflammation. Johns Hopkins Asthma & Allergy Center,
Divisional Research Conference. Baltimore, MD, October 28, 2009.
41.
Photoaging pathophysiology: an inside-out to outside-in story. The College of Physicians
of Philadelphia, Section on Dermatology, Philadelphia, PA, February 3, 2010.
42.
Nephrogenic systemic fibrosis & ultraviolet-A1 to induce skin antifibrosis. Department
of Dermatology, Johns Hopkins School of Medicine. Baltimore, MD, February 5, 2010.
43.
Aging of skin and how to prevent it. Johns Hopkins Hospital, Women’s Board.
Baltimore, MD, April 26, 2010.
44.
Meet-the-Professor in Dermatology. Topics in Clinical Medicine. Johns Hopkins
Medicine, Baltimore, MD, May 4, 2010
45.
Antagonism of skin aging by all-trans retinoic acid. Clinical Pharmacology Division,
Department of Internal Medicine, Johns Hopkins Medicine, Baltimore, MD, September
28, 2011
46.
Photoaging pathophysiology. Department of Plastic Surgery, Johns Hopkins Medicine,
Baltimore, MD, September 29, 2011
47.
Office Dermatology Pepsico Employee Health & Wellness Summit. Baltimore, MD,
October 22, 2012
48.
Harnessing UV Light to Improve Skin Fibrosis in Skin of Color. John A. Kenney, Jr.,
MD Memorial Lecture, Washington DC Dermatological Society, Walter Reed National
Medical Center, Bethesda, MD – November 16, 2012